Статті в журналах з теми "614.47 23"
Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: 614.47 23.
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "614.47 23".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
1
Kroggel, Mark, James A. Schrader, and William R. Graves. "138 Nodulation Capacity of Rhizobia Isolated from Root Zones of Maackia amurensis in Two Chinese Forests." HortScience 35, no. 3 (June 2000): 413C—413. http://dx.doi.org/10.21273/hortsci.35.3.413c.
Анотація:
Maackia amurensis Rupr. & Maxim. is a leguminous tree species possessing meritorious ornamental characteristics and is confirmed to associate with rhizobia that fix nitrogen, but few attempts to isolate symbiotically superior rhizobia have been made. Our goals were to isolate rhizobia from the root zones of indigenous trees of M. amurensis in two ecologically distinct forests in the Heilongjiang Province of China, characterize the rhizobia, and compare their effectiveness at causing nodulation of this host plant. Rhizobia were isolated and cultured from nodules that formed on seedlings grown in soils collected in May 1998, from the Maoershan (45°N, 127°E) and Liangshui (47°N, 128°E) Research Forests. Inoculants from each of the 160 isolates were applied to seedlings. A subset of 48 isolates that evoked the most nodules was partitioned by cluster analysis into 12 similarity groups based on measures of number of nodules (17.9 ± 6.5), the ratio of growth rate on two distinct media (2.26 ± 1.8), pH reaction as measured by absorption at 614 nm of bromthymol blue (0.98 ± 0.36), and tolerance to sodium chloride at 15 g/L (23 out of 48). By using single-isolate cultures of similar cellular concentration as inoculants, one isolate from each group and USDA 4349, an isolate obtained during previous research, are being compared for their capacity to infect and nodulate seedlings.
2
Munoz-Zuluaga, Carlos A., Armando Sardi, Michelle Sittig, Victoria Eskay, Carol Ann Nieroda, Farah El-Sharkawy, Arkadii Sipok, and Vadim Gushchin. "Long-term outcomes with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: An 18-year experience." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 4098. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.4098.
Анотація:
4098 Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) have become standard of care for patients with peritoneal carcinomatosis (PC) from appendiceal cancer (AC). We reviewed our experience and outcomes. Methods: A retrospective review of 614 CRS/HIPEC procedures from 1998-2016 was performed. Patient characteristics, surgical variables, and postoperative outcomes of first CRS/HIPEC were analyzed. Results: Two hundred ninety patients with PC from AC underwent 334 CRS/HIPEC’s. Median age at diagnosis and surgery was 52 (22-79) and 53 (23-81) years, respectively; 65% (187) were female. Prior surgical score was 0, 1, 2, and 3 in 20%, 38%, 37%, and 5%, respectively. Prior systemic chemotherapy was reported in 30% of patients. Median time from diagnosis to CRS/HIPEC was 4 months (0-182). Pre-operative tumor markers (CEA, CA-125, CA-19-9) were positive in 48% with one, two, and three positive markers in 21%, 15%, and 13% patients, respectively. Median Peritoneal Cancer Index was 29. Mitomycin-C was the HIPEC agent of choice. Mean operative time was 10 hours (R: 4-19) and median length of stay was 10 days (R: 4-93). Histology included 59% (171) peritoneal mucinous carcinomatosis (PMCA), 41% (119) disseminated peritoneal adenomucinosis (DPAM). Lymph nodes were positive in 47% PMCA. Complete cytoreduction rate was 87% (84% PMCA, 92% DPAM [p = 0.048]). Grade III-V complications occurred in 21%, with one 30-day mortality (0.3%). Overall, median progression-free survival (PFS) was 84 months with 5-year PFS of 56%. Median PFS was 43 months in PMCA and not reached in DPAM. Five year PFS was 40% PMCA and 82% DPAM (p < 0.001). Median overall survival (MOS) was 139 months with 61% 5-year OS. MOS was 53 months in PMCA and not reached in DPAM. Five year OS was 47% PMCA and 85% DPAM (p < 0.001). At 42-month median follow-up, 68% were alive (92 PMCA/103 DPAM) with 84% disease free (72 PMCA/92 DPAM), 28% died of disease (73 PMCA/7 DPAM). Conclusions: CRS/HIPEC is an effective treatment for patients with PC from AC providing meaningful long term survival in low and high grade tumors and should be considered the standard of care.
3
Rosenberg, Shoshana M., Ann H. Partridge, Philip Daniel Poorvu, Jacqueline N. Casillas, Patricia A. Ganz, Linda A. Jacobs, Mary S. McCabe, et al. "Fertility preservation use and outcomes among young adult cancer survivors." Journal of Clinical Oncology 36, no. 7_suppl (March 1, 2018): 115. http://dx.doi.org/10.1200/jco.2018.36.7_suppl.115.
Анотація:
115 Background: Fertility is a critical survivorship issue for young adults (YA) with cancer. Data regarding use of fertility preservation (FP) and fertility outcomes in this population are limited. Methods: In 2013-2014, 868 patients, aged 18-39, 1-5 years post diagnosis (dx) of an invasive cancer completed a survey about the impacts of cancer and treatment including fertility. Descriptive statistics were used to characterize FP options pursued, reasons for not undergoing FP, and pregnancy outcomes. Logistic regression was used to identify factors associated with pre- treatment FP. Results: Median age at dx was 32. Most respondents were female (73%), married (61%), with a college degree (71%). Breast (28%), thyroid (15%), and lymphoma (13%) were the most common dx. 13% (77/614) of women and 36% (82/231) of men reported FP attempts prior to treatment, including 57% of testicular, 39% of lymphoma, 27% of leukemia, and 18% of breast cancer survivors. In men, sperm banking (96%) was the most common approach; in women, embryo (47%) and oocyte (23%) cryopreservation. Of those who did not pursue FP (N=686), 19% reported lack of information on risks/options as the reason. In multivariable analyses, FP was associated (p<0.05) with male gender, younger age, chemotherapy, being married, and having a college degree; survivors who had children prior to dx were less likely to pursue FP (Table). Of 60 men who tried to father a pregnancy, 42 (70%) were successful and 37 (88%) conceived naturally. Of 114 women who attempted pregnancy, 83 (73%) were successful, 76 (92%) conceived naturally. Conclusions: Some YA patients are not aware of treatment risks and FP options, indicating that fertility may be under-addressed. In our sample, nearly all patients who reported attempting pregnancy within 5 years of dx conceived naturally, suggesting that a risk stratified approach may help optimize use of FP services. [Table: see text]
4
Korsakova, Yu L., T. V. Korotaeva, E. Yu Loginova, E. E. Gubar, E. A. Vasilenko, A. A. Vasilenko, N. A. Kuznetsova, I. M. Patrikeeva, and E. L. Nasonov. "The prevalence of comorbid and concomitant diseases in psoriatic arthritis patients, data from Russian register." Rheumatology Science and Practice 59, no. 3 (July 15, 2021): 275–81. http://dx.doi.org/10.47360/1995-4484-2021-275-281.
Анотація:
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis associated with psoriasis (Ps); it belongs to the group of spondyloarthritis and is accompanied by damage to both the spine and peripheral joints, as well as the development of enteritis and dactylitis. In addition to skin and joint damage, PsA has numerous comorbid conditions that are pathogenetically related to the underlying disease, such as inflammatory bowel disease (IBD) and autoimmune eye disease, as well as cardiovascular diseases, obesity and metabolic syndrome, diabetes, osteoporosis, malignancies, mental disorders, and various concomitant diseases. We present data of the prevalence of these pathological conditions among the cohort of PsA patients included in the Russian register.Objective – to study the prevalence of comorbid and concomitant diseases in PsA patients.Materials and methods. The Russian multicenter, observational study with retrospective and prospective data collection of PsA patients included 614 patients with the established diagnosis psoriatic arthritis, corresponding to the CASPAR criteria, from 39 subjects of the Russian Federation, female/male – 331 (54%)/283 (46%). The average age was 45.2±0.52 years, duration of PsA – 5.7±0.27 years, Ps – 15.71±0.56. Duration of observation period: January 2016 – November 26, 2019. The diagnosis of comorbid and concomitant diseases was confirmed by medical specialists in accordance with the ICD-10 code. The analysis of the frequency and structure (%) of these diseases was carried out.Results. The majority of PsA patients had limited Ps: the area of Ps skin lesion (BSA, Basic Surface Area) was less than 3% in 372 (61.5%) patients, BSA from 3% to 10% – in 185 (30.6%), BSA>10% – in 47 (7.8%). Comorbid and concomitant diseases were detected in 297 (48%) of 614 patients. 183 (61.6%) patients had 2 or more diseases in addition to Ps and PsA. Diseases of the circulatory system were detected in 229 (77.1%) PsA patients with comorbid and concomitant diseases (arterial hypertension – in 194 (65.3%), coronary heart disease – in 22 (7.4%)). Diseases of the endocrine system, metabolic disorders were detected in 156 (52.5%) patients with PsA (diabetes mellitus in 44 (14.8%), hyperlipidemia in 44 (14.8%), metabolic syndrome in 36 (12.1%), obesity in 7 (2.4%), and others). Gastrointestinal diseases were observed in 62 (20.9%) patients. Diseases of the biliary system – in 33 (11.1%) patients. Diseases of the musculoskeletal system and connective tissue that are not associated with PsA – in 44 (14.8%). Diseases of the genitourinary system – in 23 (7.7%) patients. Respiratory diseases – in 17 (5.7%) patients. Infectious diseases – in 11 (3.7%). Eye diseases were detected – in 10 (3.4%) patients. Hematological diseases were diagnosed in 6 (2.0%) patients. Depression – in 4 (1.3%) patients.Conclusions. Among 297 patients with PsA with comorbid and concomitant diseases, diseases of the circulatory system are the most common (in 77.1%), less often – diseases of the endocrine system, metabolic disorders (in 52.5%) and diseases of the digestive system (in 32%). Uveitis (2.7%), IBD (1.3%), and depression (1.3%) were rarely detected in our cohort. The majority of patients in the Russian registry had mild forms of Ps (61.5%), and severe Ps (BSA>10%) was observed only in 7.8%. Thus, PsA is associated with a high prevalence of comorbid and concomitant diseases, especially cardiovascular. When choosing a treatment, these diseases should be taken into account. In connection with the new possibilities of therapy, it is necessary to evaluate the potential impact of therapy on patients with comorbid and concomitant diseases in real clinical practice.
5
Tabak, Fehmi, Esra Zerdali, Ozlem Altuntaş, Alper Gunduz, Sibel Bolukcu, Bilgul Mete, Inci Y. Nakir, et al. "Efficacy and safety of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-positive patients: real-world data." International Journal of STD & AIDS 32, no. 6 (February 18, 2021): 562–69. http://dx.doi.org/10.1177/0956462420983692.
Анотація:
Objectives: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a recommended and widely used regimen for HIV infection. In this study, we aimed to determine the efficacy and safety of E/C/F/TAF in people living with HIV (PLWH), who are either treatment-naïve or switched from any tenofovir disoproxil fumarate-containing regimen. For switched patients, we aimed to determine the impact of switching from tenofovir disoproxil fumarate (TDF) to TAF on lipid profile and kidney functions. Methods: ACTHIV-IST Study Group produced a database, and five dedicated HIV centres in Istanbul entered data of PLWH who switched from any TDF-containing regimen to E/C/F/TAF and treatment-naïve patients who were initiated with the E/C/F/TAF regimen between January 2017 and December 2019. Clinical findings, viral parameters, lipid studies, renal function tests, adverse events and adherence to the treatment were recorded in this prospective observational study. Results: The study included a total of 614 switched and treatment-naïve patients. Of 430 treatment-experienced patients, 89% (382) were men, and the mean age was 42 ± 12 years. Among them, 47% (181/382) self-identified as men who have sex with men (MSM). The median duration of HIV diagnosis was 54 ± 29 months. The median duration of E/C/F/TAF use was 20 ± 36 months and that of previous treatment was 23 ± 18 months. HIV-RNA was undetectable at baseline and month 12 in 84.1% (360/428) and 86.1% (328/381) of patients, respectively ( p > 0.05). Mean CD4 counts were 708 ± 287 cells/µL and 802 ± 305 cells/µL at baseline and month 12, respectively ( p < 0.001). Serum creatinine levels remained stable during the treatment period. Mean total cholesterol levels at baseline and month 12 were 172 and 211 mg/dL ( p < 0.01), LDL-cholesterol 104 and 138 mg/dL ( p < 0.01), HDL-cholesterol 39 and 49 mg/dL ( p < 0.01) and triglycerides 134 and 174 mg/dL ( p < 0.01), respectively. The treatment was generally well tolerated. Eight patients discontinued the therapy (drug interaction: 3; lost to follow-up: 1; pregnancy: 1; pulmonary tuberculosis: 1; side effect: 1; patient’s decision: 1). Of 184 treatment-naïve patients, 88% (162) were men, and the mean age was 36.5± 12 years. Among them, 50% (81/162) self-identified as MSM. The mean duration of HIV infection was 21.6 ± 17.1 months. The mean duration of E/C/F/TAF use was 16 ± 4 months. HIV-RNA was undetectable at baseline and month 12 in 1% and 89.1% of patients, respectively. Mean CD4 counts at baseline and month 12 were 469 ± 223 cells/µL and 740 ± 298 cells/µL, respectively. During the treatment period, creatinine levels remained stable. Total cholesterol, LDL-cholesterol, triglyceride and also HDL-cholesterol levels increased. Mean total cholesterol levels at baseline and month 12 were 167 and 211 mg/dL ( p < 0.01), LDL-cholesterol 108 and 143 mg/dL ( p < 0.01), HDL-cholesterol 41 and 47 mg/dL ( p < 0.01) and triglycerides 136 and 172 mg/dL, respectively ( p < 0.01). The treatment was generally well tolerated. Three patients discontinued the therapy (drug interaction: 1; non-responder: 1; patient’s decision: 1). Conclusion: Starting with or switching to E/C/F/TAF in PLWH effectively suppresses HIV infection, is associated with an increase in CD4 cell count and is well tolerated in a real-life setting. Renal functions remained stable during the treatment. E/C/F/TAF use was associated with an increase in LDL-cholesterol and triglyceride levels along with an increase in HDL-cholesterol levels.
6
Ritenour, Andrew, Volodymyr Bondarenko, Robin L. Kelley, and David C. Sheridan. "Electrical Characterization of Large Area 800 V Enhancement-Mode SiC VJFETs for High Temperature Applications." Materials Science Forum 615-617 (March 2009): 715–18. http://dx.doi.org/10.4028/www.scientific.net/msf.615-617.715.
Анотація:
Prototype 800 V, 47 A enhancement-mode SiC VJFETs have been developed for high temperature operation (250 °C). With an active area of 23 mm2 and target threshold voltage of +1.25 V, these devices exhibited a 28 m room temperature on-resistance and excellent blocking characteristics at elevated temperature. With improved device packaging, on-resistance and saturation current values of 15 m and 100 A, respectively, are achievable.
7
Mastronardi, Luciano, Ahmed Elsawaf, Raffaelino Roperto, Alessandro Bozzao, Manuela Caroli, Michele Ferrante, and Luigi Ferrante. "Prognostic relevance of the postoperative evolution of intramedullary spinal cord changes in signal intensity on magnetic resonance imaging after anterior decompression for cervical spondylotic myelopathy." Journal of Neurosurgery: Spine 7, no. 6 (December 2007): 615–22. http://dx.doi.org/10.3171/spi-07/12/615.
Анотація:
Object Areas of intramedullary signal intensity changes (hypointensity on T1-weighted magnetic resonance [MR] images and hyperintensity on T2-weighted MR images) in patients with cervical spondylotic myelopathy (CSM) have been described by several investigators. The role of postoperative evolution of these alterations is still not well known. Methods A total of 47 patients underwent MR imaging before and at the end of the surgical procedure (intraoperative MR imaging [iMRI]) for cervical spine decompression and fusion using an anterior approach. Imaging was performed with a 1.5-tesla scanner integrated with the operative room (BrainSuite). Patients were followed clinically and evaluated using the Japanese Orthopaedic Association (JOA) and Nurick scales and also underwent MR imaging 3 and 6 months after surgery. Results Preoperative MR imaging showed an alteration (from the normal) of the intramedullary signal in 37 (78.7%) of 47 cases. In 23 cases, signal changes were altered on both T1- and T2-weighted images, and in 14 cases only on T2-weighted images. In 12 (52.2%) of the 23 cases, regression of hyperintensity on T2-weighted imaging was observed postoperatively. In 4 (17.4%) of these 23 cases, regression of hyperintensity was observed during the iMRI at the end of surgery. Residual compression on postoperative iMRI was not detected in any patients. A nonsignificant correlation was observed between postoperative expansion of the transverse diameter of the spinal cord at the level of maximal compression and the postoperative JOA score and Nurick grade. A statistically significant correlation was observed between the surgical result and the length of a patient's clinical history. A significant correlation was also observed according to the preoperative presence of intramedullary signal alteration. The best results were found in patients without spinal cord changes of signal, acceptable results were observed in the presence of changes on T2-weighted imaging only, and the worst results were observed in patients with spinal cord signal changes on both T1- and T2-weighted imaging. Finally, a statistically significant correlation was observed between patients with postoperative spinal cord signal change regression and better outcomes. Conclusions Intramedullary spinal cord changes in signal intensity in patients with CSM can be reversible (hyperintensity on T2-weighted imaging) or nonreversible (hypointensity on T1-weighted imaging). The regression of areas of hyperintensity on T2-weighted imaging is associated with a better prognosis, whereas the T1-weighted hypointensity is an expression of irreversible damage and, therefore, the worst prognosis. The preliminary experience with this patient series appears to exclude a relationship between the time of signal intensity recovery and outcome of CSM.
8
Sergueeva, Adelina, Galina Miasnikova, Ekaterina Lisina, Mehdi Nouraie, Sergei A. Nekhai, Tatiana Ammosova, Josef T. Prchal, Xu Zhang, and Victor R. Gordeuk. "Thrombotic Complications Are Associated with Phlebotomy Therapy in Patients with Chuvash Polycythemia." Blood 126, no. 23 (December 3, 2015): 936. http://dx.doi.org/10.1182/blood.v126.23.936.936.
Анотація:
Abstract Background: In Chuvash polycythemia (CP) (Problemi Gematologii I Perelivaniya Krovi 1974, 10:30), impaired degradation of hypoxia inducible factor (HIF)-1α and HIF-2α from a homozygous germline VHLR200W mutation leads to augmented hypoxic responses during normoxia (Nat Genet 2002, 32:614). In addition to elevated hematocrit, CP is marked by leg varices, benign vertebral hemangiomas, decreased systemic blood pressure, increased systolic pulmonary artery pressure, and by the defining phenotypes of thrombosis and early mortality (Blood 2004, 103:3924; Haematologica 2012, 97:193). There is no effective therapy. While phlebotomy has been recommended for idiopathic polycythemia by the British Committee for Standards in Haematology (Br J Haematol 2005, 130:174) and is administered to some CP patients, its benefits are unknown. Phlebotomy-induced iron deficiency inhibits PHD2 enzyme, the principal negative regulator of HIFs, which further augments hypoxic responses. This affects the transcription of many genes (BCMD 2014, 52:35). Hypoxia-regulated IRAK1 is augmented in inflammation and may promote thrombosis (Circ Res. 2013, 112:103). Methods: 165 patients with CP were enrolled in a registry between 2001 and 2009 after providing written informed consent. Survival analysis was used to examine the predictors of new thrombosis and death during the follow-up period. mRNA from peripheral blood mononuclear cells (PBMCs) was profiled by Affymetrix Human Exon 1.0 ST Array in 42 of the subjects. Results: The median age at enrollment was 35 years and 90 participants were females, 25 had a history of one thrombosis, 5 of two thromboses and 3 of three thromboses. In the year prior to study entry, 72 had received phlebotomy therapy (Table 1). In July 2015 the median follow-up was 9.0 years (range 1-14.5). During this follow-up period, 30 (18.2%) participants had one new thrombosis, 6 (3.6%) had two new thromboses and 17 (10.3%) died. The median age of death was 55 years (range 16-76) and deaths were related to thrombotic cerebrovascular accident (n = 4), myocardial infarction (n = 4), mesenteric or portal vein thrombosis (n = 3), other major thromboembolic events (n = 2) and trauma or unknown cause (n = 2). Baseline characteristics of older age, prior thrombosis, pentoxifylline treatment, smoking and splenomegaly were independently associated with greater thrombosis risk during follow-up (P < 0.003). After adjustment for these variables, the estimated probability of new thrombosis at 10 years was 26% in those receiving phlebotomies compared to 12% in those not phlebotomized (log rank P = 0.014) (Figure 1). There was also a trend for increased risk of death with phlebotomy: estimated probability 8.7% versus 3.7% (P = 0.15). Examination of gene transcripts affecting thrombosis by logistic regression identified 12 protective and 16 risk genes at 5% false discovery rate. Upregulation of two mRNAs was of singular significance: 1) IL1RAP, a proximal signaling adaptor of IRAK1 (Immunity 1997, 7: 837) and 2) THBS1, encoding thrombospondin1 (Blood 2015, 125: 399). Both genes have known roles in thrombosis promotion and we previously reported that THBS1 is upregulated in CP (BCMD 2014, 52:35). Further analysis revealed a further upregulation of THBS1 in patients with baseline history of phlebotomy (β=0.41, P=0.046). Conclusion: These findings underscore a high rate of thrombosis and death in patients with CP and reveal a potential role of increased IRAK1/IL1RAP signaling in these complications. They raise the possibility that phlebotomy therapy has a detrimental rather than beneficial effect, possibly contributed to by increased THBS1 expression. Table 1. Baseline characteristics by phlebotomy in the year prior to enrollment. Results in median (interquartile range) or n (%); four without phlebotomy data. No phlebotomy N=89 Received phlebotomy N=72 Age (years) 32 (18-48) 37 (26-49) 0.08 Female gender, n (%) 52 (58%) 34 (47%) 0.16 Smoking, n (%) 18 (20%) 24 (33%) 0.060 History of thrombosis, n (%) 20 (23%) 12 (17%) 0.4 Splenomegaly, n (%) 2 (2.3%) 2 (2.8%) 0.8 ASA treatment, n (%) 27 (30%) 36 (50%) 0.011 Pentoxifylline, n (%) 7 (7.9%) 17 (23.6%) 0.005 BMI (kg/m2) 20.4 (18.3-22.9) 21.6 (19.9-24.6) 0.010 Systolic BP (mm Hg) 109 (100-123) 118 (105-124) 0.6 Diastolic BP (mm Hg) 76 (68-84) 78 (71-83) 0.8 Hemoglobin (g/dL) 18.1 (16.4-21.0) 17.9 (16.0-19.8) 0.5 WBC (per uL) 5.7 (4.6-7.0) 5.5 (4.6-6.7) 0.9 Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.
9
Fung, Isaac Chun-Hai, Elizabeth B. Blankenship, M. Elizabeth Goff, Lindsay A. Mullican, Kwun Cheung Chan, Nitin Saroha, Carmen H. Duke, Marina E. Eremeeva, King-Wa Fu, and Zion Tsz Ho Tse. "Zika-Virus-Related Photo Sharing on Pinterest and Instagram." Disaster Medicine and Public Health Preparedness 11, no. 6 (March 23, 2017): 656–59. http://dx.doi.org/10.1017/dmp.2017.23.
Анотація:
AbstractObjectivePinterest (San Francisco, CA) and Instagram (Menlo Park, CA) are 2 popular photo-sharing social media platforms among young individuals. We assessed differences between Instagram and Pinterest in relaying photographic information regarding Zika virus. Specifically, we investigated whether the percentage of Zika-virus-related photos with Spanish or Portuguese texts embedded therein was higher for Instagram than for Pinterest and whether the contents of Zika-virus-related photos shared on Pinterest were different from those shared on Instagram.MethodsWe retrieved and manually coded 616 Pinterest (key words: “zika” AND “virus”) and 616 Instagram (hashtag: #zikavirus) photos.ResultsAmong the manually coded samples, 47% (290/616) of Pinterest photos and 23% (144/616) of Instagram photos were relevant to Zika virus. Words were embedded in 57% (164/290) of relevant Pinterest photos and all 144 relevant Instagram photos. Among the photos with embedded words, photos in Spanish or Portuguese were more prevalent on Instagram (77/144, 53%) than on Pinterest (14/164, 9%). There were more Zika-virus-related photos on Instagram than on Pinterest pertinent to Zika virus prevention (59/144, 41%, versus 41/290, 14%; P<0.0001), the effects of Zika virus on pregnancy (27/144, 19%, versus 32/290, 11%; P=0.04), and Zika-virus-associated deaths (4/144, 2%, versus 0/290, 0%; P=0.01).ConclusionsPinterest and Instagram are similar platforms for Zika virus prevention communication. (Disaster Med Public Health Preparedness. 2017;11:656–659)
10
Krupa, Michał. "Recenzje." Z Badań nad Książką i Księgozbiorami Historycznymi 10 (December 11, 2019): 381–96. http://dx.doi.org/10.33077/uw.25448730.zbkh.2016.130.
Анотація:
Česko-polské kazatelské vztahy ve středověku, ed. Krzysztof Bracha, Martin Nodl, „Colloquia Mediaevalia Pragensia”, 16, Praha 2016: Filosofi a, ss. 152, ISBN 978-80-7007-451-0 – Justyna Dziadek [381-385]
Pomeranica XVIII wieku w zbiorach Archiwum Państwowego w Szczecinie. Katalog, oprac. Janina Kosman, Szczecin: Wydawnictwo „Dokument” Oficyna Archiwum Państwowego w Szczecinie, 2016, ss.191, il., ISBN 978-83-64-642-23-4 – Edward Potkowski [385-390]
Katalog starodruków Biblioteki Muzeum Polskiego w Ameryce = Catalogue of Early Printed Books from The Polish Museum of America Library, oprac. Fryderyk Rozen, Warszawa: Biblioteka Narodowa, 2015, ss. 47, 28 il., ISBN 978-83-7009-613-7 – Elżbieta Maruszak [390-393]
Ewa Repucho, Typografia kompletna. Kultura książki w twórczości Leona Urbańskiego, Wrocław: Oficyna Wydawnicza Atut, 2016, ss. 328, ISBN 978-83-7977-209-4 – Agnieszka Chamera-Nowak [394-396]
11
Schuck, Anna, Marie Götte, Judith Neukirchen, Andrea Kuendgen, Norbert Gattermann, Guido Kobbe, Ulrich Germing, and Rainer Haas. "Treatment with Azacitidine: A Retrospective Study Evaluating the Real Life Clinical Course and Impact on Infectious Complications." Blood 126, no. 23 (December 3, 2015): 1684. http://dx.doi.org/10.1182/blood.v126.23.1684.1684.
Анотація:
Abstract Introduction: Demethylating agents such as azacitidine (AZA) and decitabine have become available therapies for higher risk MDS and low blast count (20-30%) AML. Compared to intensive chemotherapy and best supportive care both agents have been found to improve overall survival rates (OS). Yet, infectious complications can impede AZA or decitabine therapy. Since most of the patients are managed on an outpatient basis with often low level of clinical and microbiological documentation, the impact of the hematological response on demethylating agents and the consequences of following infectious complications often are not well documented. Therefore, the aim of this study was to evaluate the real life incidence, character, time of occurrence and clinical role of infectious complications of MDS patients treated with AZA at our institute and to correlate findings with hematological response. We especially focused on the amount of resulting days in hospital, mortality rates and the extent of antimicrobial therapies. Methods: We retrospectively evaluated the outcome of 77 patients with MDS treated with AZA from 08/2004 to 01/2015. All patients received AZA cycles at standard dosage (75mg/m² for 7 days every 28 days). Clinical and microbiological work-up included parameters like severity and kind of infectious complication, days as an inpatient and days with antimicrobial therapy, response to therapy, and overall survival (OS). Results: Between August 2004 and January 2015, 77 MDS patients (M/F 57%/43%, median age 69 years, range 41-81 years) treated with azacitidine were included in the study. IPSS-R was high or very high in 57 % of the cases. The median number of administered AZA cycles was 6 (range 1-43 cycles). The response rates were 18% complete remission (CR), 26% partial remission (PR), 6% hematological improvement (HI), 18% stable disease (SD) and 34% progressive disease (PD). Median overall survival was 12 months (range 1-103). In Kaplan-Meyer-curve analysis AZA showed a trisection of all patients in three groups with significantly different survival, as well as incidence and duration of infectious complications. In the first group were all patients who reached a CR with a median OS of 37 months (range 7-72), a median of 0 cycles as an inpatient (range 0-4), 6% complication rate per cycle with a median of 6 (range 2-9) days of i.v. antibiotics and no days of i.v. antimycotics per complication and a median of 3.5 (range 0-84) days in hospital during all cycles. In the second group were all patients who reached PR or HI with a median OS of 23 months (range 1-103), a median of 0 cycles as an inpatient (range 0-7), 10% complication rate per cycle with a median of 8 (1-19) days of i.v. antibiotics and 10.5 (10-11) days of i.v. antimycotics and a median of 9 (range 0-115) days in hospital during all cycles. In the third group were all patients who remained stable or progressed with a median OS of 11 months (range 0-67), a median of 0 cycles as an inpatient (range 0-6), 32 % complication rate per cycle with a median of 9 (3-47) days of i.v. antibiotics and 10 (3-28) days of i.v. antimycotics and a median of 16 days in hospital during all cycles (range 0-78). In total, 614 treatment cycles were administered, and 81 infectious complications occurred. 18% of all infectious complications were lung infections documented by chest CT, 15% skin-/soft tissue infections, 10 % gastrointestinal infections, 3 % urinary tract infections and 58 % infections of unknown origin. Looking at all documented AEs (n=100), 36 were documented in the first 2 cycles of treatment, 30 during the cycles 3-5 and 22 after the fifth cycle. Conclusion: The clinical course, incidence of infectious complications and the outcome of patients treated with 5-Azazytidine can be trisected in 3 groups only according to their hematological response. Therefore, any response, even only HI, diminishes the incidence rate of infectious complications and improves the outcome of patients. Of note, patients with stable disease had the same outcome and infection rates as patients with progressive disease. The best clinical course and outcome was seen in patients with complete remission. Most of the infectious complications occurred during the first treatment cycles. An early treatment response seems to reduce the incidence of infections and days in hospital and improves the overall outcome. Disclosures Neukirchen: Novartis: Membership on an entity's Board of Directors or advisory committees. Gattermann:Novartis: Honoraria, Research Funding.
12
Trimankha, Pilawan, Lakkana Lakkana Jirapong, Runnaya Rungsin, Orawan Autravisittikul, Pariyanoot Deesuwan, M. D. Deesuwan, Yasinee Mekavuthikul, and Anocha Chodpanich. "Utility of screening chest radiographs in patients with asymptomatic and mildly symptomatic COVID-19 at a field hospital in Samut Sakhon, Thailand." ASEAN Journal of Radiology 22, no. 2 (August 25, 2021): 05–20. http://dx.doi.org/10.46475/aseanjr.v22i2.119.
Анотація:
Background: In a new episode of the COVID -19 pandemic in Thailand during the beginning of 2021, cases in Samut Sakhon Province mainly occurred in foreign workers and were mostly asymptomatic or had mild disease. To prevent overwhelming the local hospital, a field hospital was established which used chest radiography as one of screening tools for triaging patients. Objective: To determine the clinical utility of chest radiographs as a screening tool for COVID-19 patients who were asymptomatic or mildly symptomatic. Materials and Methods: Six hundred nineteen patients with COVID -19 (confirmed by reverse transcriptase-polymerase chain reaction) were registered at the field hospital at Samut Sakhon provincial sport stadium during 5-8 January 2021 and had chest radiographs taken. The image readings were based on the consensus of two radiologists and a final decision was made by a third radiologist if the first two did not agree. Findings on chest radiographs and clinical outcomes were evaluated. Results: The study included 619 radiographs; 328/619 (53%) men and 291/619 (47%) women had a mean age of 33.3+/- 9.7 (range, 5-64) years. There was mild disease in 13/619, and asymptomatic infections in 606/619. Chest radiographs were normal in 568 (91.7%) and abnormal in 51 (8.3%) patients; typical findings of COVID-19 were seen in 3 (0.5%) patients. Other abnormal findings were found in 23 (3.8%) patients such as active tuberculosis in 6 (1.0%). Four patients were transferred to the hospital, one of whom required supplemental oxygen. Conclusion: Combined chest radiographic and clinical information allows better decisions regarding hospital transfers of asymptomatic and mildly symptomatic COVID-19 patients at a field hospital.
13
Kuo, John, Omid R. Hariri, Galyna Bondar, Julie Ogi та Paul Micevych. "Membrane Estrogen Receptor-α Interacts with Metabotropic Glutamate Receptor Type 1a to Mobilize Intracellular Calcium in Hypothalamic Astrocytes". Endocrinology 150, № 3 (23 жовтня 2008): 1369–76. http://dx.doi.org/10.1210/en.2008-0994.
Анотація:
Estradiol, acting on a membrane-associated estrogen receptor-α (mERα), induces an increase in free cytoplasmic calcium concentration ([Ca2+]i) needed for progesterone synthesis in hypothalamic astrocytes. To determine whether rapid estradiol signaling involves an interaction of mERα with metabotropic glutamate receptor type 1a (mGluR1a), changes in [Ca2+]i were monitored with the calcium indicator, Fluo-4 AM, in primary cultures of female postpubertal hypothalamic astrocytes. 17β-Estradiol over a range of 1 nm to 100 nm induced a maximal increase in [Ca2+]i flux measured as a change in relative fluorescence [ΔF Ca2+ = 615 ± 36 to 641 ± 47 relative fluorescent units (RFU)], whereas 0.1 nm of estradiol stimulated a moderate [Ca2+]i increase (275 ± 16 RFU). The rapid estradiol-induced [Ca2+]i flux was blocked with 1 μm of the estrogen receptor antagonist ICI 182,780 (635 ± 24 vs. 102 ± 11 RFU, P < 0.001) and 20 nmof the mGluR1a antagonist LY 367385 (617 ± 35 vs. 133 ± 20 RFU, P < 0.001). Whereas the mGluR1a receptor agonist (RS)-3,5-dihydroxyphenyl-glycine (50 μm) also stimulated a robust [Ca2+]i flux (626 ± 23 RFU), combined treatment of estradiol (1 nm) plus (RS)-3,5-dihydroxyphenyl-glycine (50 μm) augmented the [Ca2+]i response (762 ± 17 RFU) compared with either compound alone (P < 0.001). Coimmunoprecipitation demonstrated a direct physical interaction between mERα and mGluR1a in the plasma membrane of hypothalamic astrocytes. These results indicate that mERα acts through mGluR1a, and mGluR1a activation facilitates the estradiol response, suggesting that neural activity can modify estradiol-induced membrane signaling in astrocytes. For rapid 17β-estradiol-induced membrane signaling in hypothalamic astrocytes, mER-α must interact with mGluR1a resulting in a dramatic increase in free cytoplasmic calcium concentration within seconds.
14
Бекетова, Н. А., В. М. Коденцова, С. Н. Леоненко, О. В. Кошелева, О. А. Вржесинская, С. Х. Сото, А. А. Сокольников, Л. В. Шевякова та Н. В. Жилинская. "ВЛИЯНИЕ ОБОГАЩЕНИЯ РАЦИОНА КРЫС ИНУЛИНОМ НА УСВОЕНИЕ НЕКОТОРЫХ ВИТАМИНОВ И МИНЕРАЛЬНЫХ ВЕЩЕСТВ". Trace Elements in Medicine (Moscow) 22, № 3 (вересень 2021): 47–57. http://dx.doi.org/10.19112/2413-6174-2021-22-3-47-57.
Анотація:
Исследовано влияние введения в рацион растворимых пищевых волокон (5% инулина) на коррекцию дефицита витаминов D и группы В и его последствий у растущих крыс-самцов Wistar (масса тела 51,4±0,5 г) после возникшего у них дефицита, вызванного уменьшением содержания витаминов D и группы В в витаминной смеси полусинтетического рациона в течение 23 сут. Обогащение рациона крыс инулином не влияло на усвоение витаминов А и D дефицитными животными в ходе 7-дневной коррекции витаминного статуса, несколько замедляло восстановление нормальной обеспеченности витаминами В1 и В6 (по экскреции с мочой), В2 (по содержанию в мозге). При этом содержание витамина Е в печени было снижено в 1,48 раза по сравнению с контрольной группой, концентрация железа в плазме крови повышена на 32,7%, в печени на 42,6%, содержание марганца в головном мозге повышено в 1,5 раза, что не выходит за пределы физиологической нормы. Это свидетельствует о целесообразности обогащения инулином рациона лиц с железодефицитными состояниями при одновременном обогащении витаминами Е и группы В.
15
Shevchenko, O. P., E. A. Stakhanova, A. O. Shevchenko, N. P. Mogeiko, and O. E. Gichkun. "VASCULAR ENDOTHELIAL GROWTH FACTORS IN HEART TRANSPLANT REJECTIONS." Russian Journal of Transplantology and Artificial Organs 17, no. 2 (May 26, 2015): 23–29. http://dx.doi.org/10.15825/1995-1191-2015-2-23-29.
Анотація:
Aim:to determine the clinical significance of vascular endothelial growth factors VEGF-A, VEGF-D, PlGF-1 to assess the risk of cardiovascular complications in heart recipients.Materials and methods.103 patients, aged 16 to 73 years, 85 males and 18 females. 65 recipients (47 men and 18 women) had dilated cardiomyopathy, 38 – coronary heart disease (CHD). The concentration of VEGF-A, VEGF-D, PlGF-1 was measured using xMAP technology with sets of reagents Simplex ProcartaPlex™.Results.After HTx the level of VEGF-A significantly decreased, p = 0.001. There were no correlations between the levels of VEGF-A, VEGF-D and PlGF-1 with age, gender and diagnosis. After HTx VEGF-A level was higher in recipients with ACR than in those without it (p = 0.001). ACR frequency was significantly higher in patients with high VEGF-A level (≥316.5 pg/ml, RR = 5.8 ± 0.5, AUC = 0.779). After HTx PlGF-1 level was higher in recipients with ACR too (p = 0.039). ACR frequency was significantly higher in patients with high PlGF-1 level (≥5.33 pg/ml, RR = 1.8 ± 0.5, AUC = 0.65). There were no correlations between VEGF-D level with ACR and all three biomarkers with AMR. ACR frequency was significantly higher with both high VEGF-A and PlGF-1 levels (RR = 6.4).Conclusion.Serum levels of VEGF-A and PlGF-1 after HTx may be regarded as indicators of increased risk of ACR.
16
Hong, Seokchan, Byeongzu Ghang, Yong-Gil Kim, Chang-Keun Lee, and Bin Yoo. "Longterm Outcomes of Renal Artery Involvement in Takayasu Arteritis." Journal of Rheumatology 44, no. 4 (February 15, 2017): 466–72. http://dx.doi.org/10.3899/jrheum.160974.
Анотація:
Objective.Takayasu arteritis (TA) involving the renal artery can result in hypertension (HTN), renal dysfunction, and premature death. The aim of this study was to investigate the longterm outcomes and factors that predict outcomes in patients with TA with renal artery stenosis.Methods.The medical records of patients diagnosed with TA between January 1997 and December 2014 were reviewed retrospectively. Renal artery involvement was based on computed tomography and/or angiography findings. Poor outcome was defined as refractory HTN, chronic renal insufficiency, or death.Results.Of the 62 TA patients with renal artery involvement, 11 (17.7%) underwent renal artery revascularization. Younger age, male sex, and more severe stenosis (> 70%) were associated with vascular intervention. After a median followup of 90.6 months, 11 (17.7%) of the 62 patients had refractory HTN and 6 (9.7%) had chronic renal insufficiency. Renal insufficiency [5/15 (33.3%) vs 3/47 (6.4%), p = 0.016] and bilateral involvement [12/15 (80.0%) vs 23/47 (48.9%), p = 0.041] were significantly more frequent in patients with poor than good outcomes. Multivariate Cox analysis revealed that renal insufficiency at presentation (HR 13.778, 95% CI 3.530–53.786, p < 0.001) and bilateral renal artery involvement (HR 5.053, 95% CI 1.179–21.661, p = 0.029) were significant risk factors for poor outcomes at followup, but performance of revascularization procedure was not (HR 0.663, 95% CI 0.176–2.498, p = 0.543).Conclusion.Bilateral lesions and renal functional impairment at presentation, but not implementation of revascularization procedures, were significant factors for outcomes in TA patients with renal artery involvement.
17
SUASSUNA, Lívia, and Sabrina Leite FELIX. "SABERES EM MOVIMENTO NO ESTÁGIO DE REGÊNCIA DE TURMA: O ENSINO DE ANÁLISE LINGUÍSTICA POR GRADUANDOS DE LETRAS." Trama 17, no. 41 (June 1, 2021): 09–27. http://dx.doi.org/10.48075/rt.v17i41.26732.
Анотація:
Neste estudo pretendemos analisar o modo como alunos da licenciatura em Letras-Português da Universidade Federal de Pernambuco, durante o estágio curricular, atuam para ensinar seus alunos a refletir sobre a língua, concretizando um dos eixos de ensino desse componente curricular que é a análise linguística. A pesquisa, do tipo qualitativo-descritiva, teve como corpus projetos e relatórios de estágio, além de depoimentos dos estagiários, captados no seminário de encerramento das atividades de regência de turma do ensino fundamental. Para montar o referencial teórico, buscamos autores que tratam da formação docente, do estágio e do ensino de análise linguística. Os resultados mostraram que os futuros professores trabalham numa perspectiva sociointeracionista e exploram uma diversidade de gêneros textuais, como indicado nas orientações mais recentes para o ensino de língua portuguesa. No entanto, a maioria deles explicita pouco os procedimentos didáticos realizados, não indica as dificuldades dos alunos quando da avaliação da aprendizagem e aborda determinados conhecimentos linguísticos de forma expositiva e dedutiva.Referências:ALMEIDA FILHO, J. C. Crise, transições e mudança no currículo de formação de professores de línguas. In: FORTKAMP, M. B. M.; TOMITCH, L. M.B. (org.). Aspectos da linguística aplicada: estudos em homenagem ao professor Hilário Inácio Bohn. Florianópolis: Insular, 2000. p. 33-47.AZEVEDO, T. M. Ensinar gêneros? Desenredo, Passo Fundo, RS, v. 10, n. 1, p. 92-103 - jan./jun. 2014.AZEVEDO, T. M. Transposição didática de gêneros discursivos: algumas reflexões. Desenredo. Passo Fundo, RS, v. 6, n. 2, p. 198-214 - jul./dez. 2010.BARBOSA, J. Análise e reflexão sobre a língua e as linguagens: ferramentas para os letramentos. In: RANGEL, E. O.; ROJO, R. H. R. (org.) Língua Portuguesa no Ensino Fundamental. Coleção Explorando o Ensino. vol. 19. Brasília: MEC/SEB, 2010, p. 155-182.CALLIAN, G. R.; BOTELHO, L. S. A análise linguística e o ensino de língua portuguesa: em busca do desenvolvimento da competência discursiva. Educação em Destaque. Juiz de Fora, MG, v. 5, n. 1, p. 1-21, 2014.DICKEL, A. Ensino de gramática: das polêmicas às proposições. In: SEMINÁRIO NACIONAL SOBRE LINGUAGENS E ENSINO, 7, 2012, Pelotas. Anais... Pelotas: UCPel, 2012.DUTRA. C. M. D.; LOULA, L. D. Incompreensão e desalinhamento teórico-metodológico como possíveis entraves à prática de análise linguística em sala de aula. Domínios de Lingu@gem, Uberlândia, MG, vol. 11, n. 3, p. 526-547, jul./set. 2017.EMILIO, A. Gramática, deve-se ou não se deve ensinar? Línguas Letras. Cascavel, PR, v. 9. n. 16, p. 27-35. 2007.GERALDI, J. W. Concepções de linguagem e ensino de português. In: GERALDI, J. W. (org.). O texto na sala de aula. São Paulo: Ática, 1997[1984], p. 39-46.GERALDI, J. W. Unidades básicas do ensino de português. In: GERALDI, J. W. (org.). O texto na sala de aula: leitura e produção. Cascavel: Assoeste, 1984, p. 49-69.LARROSA, Jorge. Algunas notas sobre la experiencia y sus lenguajes. In: BARBOSA, R. L. L. (org.). Trajetórias e perspectivas da formação de educadores. São Paulo: Ed. Unesp, 2004. p.19-34.LOMBARDI, R. F. e ARBOLEA, T. A. Formando professores pesquisadores do ensino de língua materna. In: CONGRESSO LATINO-AMERICANO SOBRE FORMAÇÃO DE PROFESSORES DE LÍNGUA. 1, Florianópolis, Anais... 2006, p. 614-619.MENDONÇA, M. Análise linguística: por que e como avaliar. In: Marcuschi, B. SUASSUNA, L. (org.). Avaliação em língua portuguesa: contribuições para a prática pedagógica. Belo Horizonte: Autêntica, 2007, p. 95-110.NÓBREGA, J. J.; SUASSUNA, L. Aula de gramática ou de análise linguística? Investigando objetos de estudo e objetivos norteadores. Linguagens, Educação e Sociedade. Teresina, PI, n. 31, p. 246-269, jul. 2014.OLIVEIRA, M. B. F. Revisitando a formação de professores de língua materna: teoria, prática e construção de identidades. Linguagem em (Dis)curso. Tubarão, SC, v. 6, n. 1, p. 101-117, jan./abr. 2006.PETRONI, M. R.; JUSTINO, A. R.; MELO, E. S. O. Ainda sobre a formação do professor de língua portuguesa no Brasil. Interacções, Santarém, PT, n. 19, p. 28-37, 2011.PIMENTA, S. G.; LIMA, M. S. L. Estágio e docência: diferentes concepções. Poiésis. Tubarão, SC, vol. 3, números 3 e 4, p. 5-24, 2006.RAUBER, A. L. A formação do professor de Língua Portuguesa: o diálogo entre teoria e prática. In: MAGALHÃES, J. S.; TRAVAGLIA, L. C. (org.). Múltiplas perspectivas em linguística. Uberlândia/MG: EDUFU, 2008, v. 01, p. 346-356.REINALDO, M. A. G. M. O conceito de análise linguística como eixo de ensino de língua portuguesa no Brasil. Estudos Linguísticos, n. 8. Edições Colibri/CLUNL, Lisboa, p. 229-241, 2012.REMENCHE, M. L. R.; ROHLING, N. Análise linguística e formação de professores: um discurso sobre a dicotomia teoria e prática. In: SIMPÓSIO MUNDIAL DE ESTUDOS DE LÍNGUA PORTUGUESA. SIMELP. 5, 2017. Salento. Atas... Salento: Università del Salento, 2017.SILVA, N. I. Ensino tradicional de gramática ou prática de análise linguística: uma questão de (con)tradição nas aulas de português. Revista Brasileira de Linguística Aplicada. Belo Horizonte, MG, v. 10, n. 4, p. 949-973, 2010.SILVA, W. R.; FAJARDO-TURBIN, A. E. F. Relatório de estágio supervisionado como registro da reflexão pela escrita na profissionalização do professor. Polifonia, Cuiabá, MT, v. 18, n. 23, p. 103-128, jan./jun., 2011.SIQUEIRA, R. A. R.; MESSIAS, R. A. L. Reflexão e ações na formação e atuação do professor de língua portuguesa: o diálogo como condição de autoria na prática educativa. In: Linguagem Ensino, Pelotas, RS, v.11, n.2, p.377-392, jul./dez. 2008.SUASSUNA, L. Ensino de análise linguística: situando a discussão. In: SILVA, A.; PESSOA, A. C.; LIMA, A. (org.). Ensino de gramática: reflexões sobre a língua portuguesa na escola. Belo Horizonte, MG: Autêntica Editora, 2012, p. 11-28.TARDIF, M.; LESSARD, C.; LAHAYE, L. Os professores face ao saber: esboço de uma problemática do saber docente. Teoria e Educação, Porto Alegre, RS, v. 04, p. 215-233, 1991.VIEIRA, S. R. Prática de análise linguística sem ensino de gramática? Reflexões e propostas. In: ATAÍDE, C. et al. (org.). GELNE 40 anos. Experiências teóricas e práticas nas pesquisas em Linguística e Literatura. Paulo: Blucher, 2017, p. 299-318. Recebido em 05-01-2021Revisões requeridas em 28-04-2021Aceito em 12-05-2021
18
Cobo, M., J. Martinez, A. Montesa, S. Gil-Calle, E. Villar-Chamorro, I. Ales, V. Gutierrez, G. Durán, F. Carabantes- Ocón, and M. Benavides. "Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e19013-e19013. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e19013.
Анотація:
e19013 Background: phase II trial-efficacy & toxicity of sequential erlotinib in advanced NSCLC after platinum-based CT Methods: Pts with adv NSCLC, PS 0/1, adequate renal, hepatic and bone marrow function, no PD after CT. Treatment: erlotinib 150 mg/day starting 3–4 weeks after CT until progression. Safety was evaluated monthly and tumor evaluation bimonthly. Results: 47 pts enrrolled:42(89%)stageIV & 5(11%)wet IIIB, all valid for response & toxicity. Median age 62 y(r:39 -77): 39(83%) males and 8(17%) females. Histology: adenocarcinoma 8(61.7%), bronquioloalveolar 3(6.4%), large cell 3(6.4%), squamous12(25.5%). PS 0: 23(49%), PS 1:24(51%). 38(81.9%) completed 6 cycles of CT. Response: CR: 1(2.1%), PR: 2(51.1%), EE: 22 (46%). Sequential erlotinib improved RR in 6 (12.8%), 23 (48.9) prolonged stabilization, 18 (38.3%) had progression. Median TTP and OS were 9.4 m (95% CI, 4.96–13–84), and 19.23 m (95% CI, 8.82–29.64). No significant differences in TTP according to age, sex, PS, histology or previous response to CT, but yes depending on RR to erlotinib: PR: 31.5 m (95% CI 15.37–47.63), EE: 12.8 m (95% CI, 10.58–15.03), PD: 6.3 m (95% CI, 5.36–7.3), p < 0.001; and moreover depending on smoking status: Never: 21.67 m(95% CI, 5.39–37.94), previous smoker > 5 years: 14.03 m(95% CI, 10.77–17.30), previous smoker 1 year: 7.77 m(95% CI, 7.62–7.91), current smoker: 5.9 m(95% CI, 5.12–6.34), p <0.001. In Cox-regression model, smoking status ( p< 0.001), and response to erlotinib (p=0.002) were associated with a significant difference in TTP. Similar results in OS, although in Cox-regression model only never smoker or > 5 years previous smoker pts had a significant better survival. Toxicity: The most frequent was skin rash, grade (g) 1 in 11(23.4%), g 2: 16(34%) and g 3: 3(6.4%). Only 1 p had diarrea g 3, and no other side effects were observed. We found a significant benefit in p with g 2–3 skin toxicity respect g 0–1, in both TTP( p= 0.0003) and OS (p= 0.0014). Conclusions: Erlotinib-maintenance therapy after platinum-based CT had promising results. Pts with the best benefit were those with response to erlotinib, in never or past (> 5 years) smokers and with g 2–3 skin toxicity. No significant financial relationships to disclose.
19
Bandeira, Francisco, Luiz Griz, Gustavo Caldas, Cristina Bandeira, and Eduardo Freese. "From mild to severe primary hyperparathyroidism: the Brazilian experience." Arquivos Brasileiros de Endocrinologia & Metabologia 50, no. 4 (August 2006): 657–63. http://dx.doi.org/10.1590/s0004-27302006000400011.
Анотація:
Primary hyperparathyroidism often presents as an asymptomatic disorder. In our institution, routine serum calcium measurements have now been used as part of medical examination for 23 years. Out of 124 patients consecutively seen at our institution, 47% presented with no symptoms related to the disease, while 25% presented with severe skeletal involvement and osteitis fibrosa cystica, 25% with renal stone disease without overt bone involvement, and 2% with the typical neuropsychiatric syndrome. This same pattern is seen in the city of São Paulo. In severe disease pathological fractures are frequently seen, especially in long bones of the lower extremities, and also loss of lamina dura of the teeth and salt-and-pepper appearance of the skull. Bone mineral density is extremely low in these patients but usually show remarkable recovery following surgical cure. Serum PTH and bone markers are considerable higher in severely affected patients, who also have a high rate of vitamin D deficiency, and the parathyroid lesion is easier located compared with asymptomatic patients. From pathological specimens 87% had histological confirmation of a single adenoma, 6.4% multiple gland hyperplasia and 3.8% carcinoma.
20
Martins, Suzana Ehlin, Lucia Rossi, Paulo de Salles Penteado Sampaio, and Mara Angelina Galvão Magenta. "Caracterização florística de comunidades vegetais de restinga em Bertioga, SP, Brasil." Acta Botanica Brasilica 22, no. 1 (March 2008): 249–74. http://dx.doi.org/10.1590/s0102-33062008000100024.
Анотація:
O município de Bertioga, no litoral central do Estado de São Paulo, apresenta grandes extensões de restingas ainda preservadas, com reduzido número de coletas de material botânico. A rápida devastação desse tipo de ambiente, por pressão de empreendedores do ramo imobiliário e outras intervenções antrópicas, torna urgente a compilação de dados que subsidiem estratégias conservacionistas. Nesse aspecto, é aqui apresentada a caracterização florística das comunidades vegetais da região que abrange as restingas de Itaguaré, São Lourenço e Guaratuba, situada entre 23º44'-23º46'S e 45º55'-46º02'W. A classificação das comunidades vegetais seguiu, sempre que possível, os critérios estabelecidos pela Resolução CONAMA n. 7/96, legislação ambiental federal, que aprova diretrizes para análise dos estágios de sucessão de vegetação de restinga para o Estado de São Paulo. Foram reconhecidas as comunidades vegetais de Praia e Dunas (33 espécies), Escrube (101), Floresta Alta de Restinga (301), Floresta Alta de Restinga Úmida (434) e Vegetação Entre Cordões (45). Foram registradas 611 espécies, representando 351 gêneros distribuídos em 106 famílias, das quais as de maior riqueza específica são: Orchidaceae (47 espécies), Myrtaceae (39), Bromeliaceae (36), Asteraceae (35), Rubiaceae (34), Fabaceae (32), Cyperaceae (23), Melastomataceae (19), Poaceae (19) e Solanaceae (15).
21
Ye, R. G., L. B. Shi, W. I. Lencer, and A. S. Verkman. "Functional colocalization of water channels and proton pumps in endosomes from kidney proximal tubule." Journal of General Physiology 93, no. 5 (May 1, 1989): 885–902. http://dx.doi.org/10.1085/jgp.93.5.885.
Анотація:
The apical membrane of mammalian proximal tubule undergoes rapid membrane cycling by exocytosis and endocytosis. Osmotic water and ATP-driven proton transport were measured in endocytic vesicles from rabbit and rat proximal tubule apical membrane labeled in vivo with the fluid phase marker fluorescein-dextran. Osmotic water permeability (Pf) was determined from the time course of fluorescein-dextran fluorescence after exposure of endosomes to an inward osmotic gradient in a stopped-flow apparatus. Pf was 0.009 (rabbit) and 0.029 cm/s (rat) (23 degrees C) and independent of osmotic gradient size. Pf in rabbit endosomes was inhibited reversibly by HgCl2 (KI = 0.2 mM) and had an activation energy of 6.4 +/- 0.5 kcal/mol (15-35 degrees C). Endosomal proton ATPase activity was measured from the time course of internal pH, measured by fluorescein-dextran fluorescence, after the addition of external ATP. Endosomes contained an ATP-driven proton pump that was sensitive to N-ethylmaleimide and insensitive to vanadate and oligomycin. In response to saturating [ATP] the pump acidified the endosomal compartment at a rate of 0.17 (rat) and 0.029 pH unit/s (rabbit); at an external pH of 7.4, the steady-state pH was 6.4 (rat) and 6.5 (rabbit). To examine whether water channels and the proton ATPase were present in the same endosome, the time course of fluorescein-dextran fluorescence was measured in response to an osmotic gradient in the presence and absence of ATP. ATP did not alter endosome Pf, but decreased the amplitude of the fluorescence signal by 43 +/- 3% (rabbit) and 47 +/- 4% (rat).(ABSTRACT TRUNCATED AT 250 WORDS)
22
Lee, CK, TS Tan, CYW Chan, and MK Kwan. "Is C1 lateral mass screw placement safe for the Chinese, Indians, and Malays? An analysis of 180 computed tomography scans." Journal of Orthopaedic Surgery 25, no. 1 (January 1, 2017): 230949901769268. http://dx.doi.org/10.1177/2309499017692683.
Анотація:
Introduction: C1 lateral mass (C1LM) screw is a common procedure in spine surgery. However, related studies are lacking in Asia. We aim to determine the safety of C1LM screw for the Chinese, Indians, and Malays. Methods: Three-dimensional computed tomographies of 180 subjects (60 from each ethnic) were analyzed. The length and angulations of C1LM screw and the location of internal carotid artery (ICA) in relation to C1LM were assessed and classified according to the classification by Murakami et al. The incidence of ponticulus posticus (PP) was determined and the differences among the population of these three ethnics were recorded. Results: The average base length was 8.5 ± 1.4 mm. The lengths within the lateral mass were between 14.7 ± 1.6 mm and 21.7 ± 2.3 mm. The prevalence of PP was 8.3%. 55.3% (199) of ICA were located in zone 0, 38.3% (138) in zone 1-1, 6.4% (23) in zone 1-2, and none in zone 1-3 and zone 2. The average angulation from the entry point to the ICA was 8.5° ± 6.4° laterally. The mean distance of ICA from C1 anterior cortex was 3.7 ± 1.7 mm (range: 0.6∼11.3). There was no difference in distribution of ICA in zone 1 among the three population (Chinese–47%, Indians–61%, and Malays–53%; p > 0.05). Conclusions: No ICA is located medial to the entry point of C1LM screw. If bicortical purchase of C1LM screw is needed, screw protrusion of less than 3 mm or medially angulated is safe for ICA. The incidence of PP is 8.3% with higher prevalence among the Indian population.
23
Arroyo Palomo, J., I. Del Bosque Granero, A. Corral Bote, B. A. Blanco Cáceres, and J. Bachiller-Corral. "AB0740 SECOND-LINE BIOLOGIC DMARDs SURVIVAL IN PSORIATIC ARTHRITIS. DATA FROM A SPANISH THIRD-LEVEL HOSPITAL." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 1665.2–1666. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4874.
Анотація:
Background:Psoriatic arthritis (PsA) covers a wide spectrum of disease manifestations, including arthritis, enthesitis, dactylitis and axial spondylitis. This range of symptoms presents a challenge to the treating physician. Biologic disease-modifying antirheumatic drugs (bDMARDs) have proven effective through randomized clinical trials; and most international PsA guides include them as main option upon first-line treatment failure. However, studies regarding drug efficacy after bDMARD switching are scarce, lower response rates and drug survival on consecutive lines has been explored in previous research.Objectives:To assess bDMARDs survival after first-line failure in PsA patients treated in a third-level hospital and to determine baseline clinical and laboratory parameters associated with drug survival.Methods:We conducted a retrospective, single-centre study. 47 patients who received a second-line bDMARD were included, with diagnosis of PsA according to the criteria of an expert rheumatologist. All patients were studied according to a standard protocol. Data regarding bDMARD prescribed, baseline characteristics, axial or peripheral involvement and immunological profile (included both HLA-B27 and HLA-Cw6) were extracted. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) at bDMARD start were included, as well. Kaplan-Meier, log-rank analyses and Cox regression models were applied.Results:Of 47 patients receiving a second bDMARD, 55,3% (26) were female and mean (S.D.) age was 40,6 (12,52) years. Median (interquartile range) disease duration was 10,1 (3,7-14,8) years. Prescribed drugs were Adalimumab (ADL) (36,2%, 17), Etanercept (ETN) (27,6%, 13), Infliximab (IFX) (6,4%, 3), Golimumab (GOL) (10,6%, 5), Certolizumab (CTZ) (4,3%, 2), Secukinumab (SCK) (8,5%, 4) and Apremilast (APR) (6,4%, 3). 42,3% cases suffered from axial involvement, rest of the sample (57,6%) presented a pure peripherical form of PsA. HLA-B27 and -Cw6 were assessed in 80,9% (38) and 68,1% (32), respectively; of whom, HLA-B27 carriers were 10,5% and HLA-Cw6 positive, 46,9%. Mean CRP level was 10,25 mg/L and mean ESR was 23,17 mm. Patients showed mean and median global drug retention of 44,57 (29,8-59,3) and 23 months. At 12-month visit, drug survival was 70%, 47% at 24 months, and 33% at 4 years from onset. Mean drug persistence by bDMARD prescribed was: ADL, 62,1 months; ETN, 51,9 months; IFX, 39 months; GOL, 22,8 months; CTZ, 9,5 months; SCK, 13,5 months; and APR, 16,3 months. Through log-rank analyses, differences in drug retention were investigated by several variables. Female sex (30,35m, 16,5-44,2 m.) was identified as statistically significant different than male patients (62,5m, 35,6-89,4m, p=0,021). Although not significant, other differences were remarkable: non-axial involvement, HLA-Cw6 negativity, HLA-B27 positivity and CRP level over 5 mg/L. No differences were found between altered and normal ESR patients.Conclusion:Second-line bDMARD survival is lower in female PsA patients, according to our data and previous bibliography. Despite our reduced sample and possible bias, non-axial involvement, absence of HLA-Cw6, presence of HLA-B27 and higher levels of CRP at biologic onset might be predictors of better drug persistence. Further investigations are required on this field.References:[1]Glintborg B et al. Clinical Response, Drug Survival, and Predictors Thereof Among 548 Patients With Psoriatic Arthritis Who Switched Tumor Necrosis Factor α Inhibitor Therapy. Results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013:65(5):1213-23.[2]Stober C et al. Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis. Rheumatology (Oxford) 2018:57(1):158-163.Table 1. Kaplan–Meier survival analysis of persistence according to sex.Table 2. Kaplan Meier survival analysis of persistence according to HLA-Cw6.Disclosure of Interests:None declared
24
Monteith, Bethany E., Esther Masih-Khan, Eshetu G. Atenafu, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, and Vishal Kukreti. "Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience." Blood 126, no. 23 (December 3, 2015): 5361. http://dx.doi.org/10.1182/blood.v126.23.5361.5361.
Анотація:
Abstract Background The incorporation of novel agents (NA) for multiple myeloma (MM) has improved the response rates (RR), overall survival (OS), and progression free survival (PFS) when compared to conventional agents (CA). Unfortunately, relapse is inevitable and few studies focus on patterns of relapse, especially in non-transplant patients (pts). We aim to describe the different patterns of relapse in non-transplant MM pts and determine if any pre-treatment clinical or disease characteristics can predict the patterns relapse. We will evaluate whether NA treated pts have higher rates of aggressive relapse with plasmacytomas or plasma cell leukemia (Leuk Res. 2009 Aug;33(8):1137-40). Secondly, RR and PFS for pts treated with CA vs NA will be described. Methods A retrospective evaluation of 156 consecutive newly diagnosed non-transplant eligible MM pts at Princess Margaret Cancer Centre receiving at least two consecutive cycles of CA or NA from 1999 to 2015. CA included steroids and alkylators while NA had immunomodulatory (IMiD) drugs (thalidomide, lenalidomide) and proteasome inhibitors (PI) (bortezomib). Response type was defined by the revised International Myeloma Working Group criteria (Leukemia. 2006 Sep;20(9):1467-73. Epub 2006 Jul 20); relapse patterns as defined in the Spanish Registry (Haematologica. 2002 Jun;87(6):609-14) Results For 156 non-transplant MM pts: 81 (52%) male, average age 76 yrs, 87 (56%) treated with NA (thalidomide=15; PI=52). Baseline characteristics were not significantly different between groups (Table 1). Sixty three (52%) pts had a clinical relapse, 37 (30%) pts had a biochemical relapse, and 22 (18%) were switched immediately to second line therapy given suboptimal response (lack of clinical benefit or PD). Six pts relapsed with isolated plasmacytomas (4 CA vs 2 NA). There was one case of plasma cell leukemia relapse in an IMiD-treated pt.Twenty seven (17.3%) pts had not relapsed at the time of analysis and had ongoing follow-up. There was no significant difference in the types of relapse patterns for pts treated with CA versus NA (p=0.26) or for CA versus IMiD versus PI therapy (p=0.22). Pts with insufficient response to first line chemotherapy were more likely to have a 17p deletion (p=0.07). All pts with a biochemical relapse did not have a 17p deletion. The median follow-up time was 16.4 (range 0.6 to 99) months (mo) for CA vs. 19.6 (range 0.4 to 107) mo for NA. Table 1. Patient Characteristics Relapse Pattern - Mean (sd) Clinicaln =63 Biochemicaln =37 Insufficient n=22 p -value Hgb 108 (17) 99 (21) 110 (18) 0.08 WBC 6.1 (2.4) 6.4 (3.3) 5.6 (1.9) 0.72 Plt 231 (107) 224 (117) 237 (103) 0.64 Ca 2.5 (0.3) 2.5 (0.4) 2.4 (0.3) 0.58 Cr 125 (92) 130 (87) 136 (133) 0.92 B2M 492 (537) 596 (448) 618 (618) 0.19 Alb 37 (7) 36 (6) 36 (5) 0.29 CRP 6.7 (7.4) 9.3 (19.1) 13.0 (17.5) 0.56 Relapse Pattern - Count (%) ConventionalNovel 35 (56)28 (44) 15 (41)22 (59) 13 (59)9 (41) 0.26 IgGIgAFLCOther 34 (54)17 (27)10 (16) 2 (3) 23 (62) 6 (16) 8 (22) 0 (0) 14 (63) 4 (18) 4 (18) 0 (0) 0.78 KappaLambda 32 (58)23 (42) 19 (59)13 (41) 12 (57)9 (43) 0.99 Chr 13 Del 8/29 (28) 7/10 (41) 3/9 (33) 0.64 t(4,14) 2/29 (7) 3/15 (20) 0/8 (0) 0.34 17p Del 4/28 (14) 0/15 (0) 3/9 (33) 0.07 Extramed. Inv. 4 (6) 1 (3) 1 (5) 0.85 Sixty (38%) pts achieved VGPR/CR/sCR, 53 (34%) PR, 35 (22%) SD, and 8 (5%) PD with upfront therapy. VGPR/CR/sCR was seen in 13 (21%) pts with CA vs 47 (78%) with NA (p<0.01). For NA, 28 (47%) pts in the PI-based group achieved VGPR/CR/sCR compared to 19 (32%) in IMiD-based (p<0.01). The median PFS for all pts was 21 (95% CI 17-23) mo, with 17 (95% CI 13-23) mo for CA vs 23 (95% CI 17-29) mo in NA. There is a statistically significant difference between CA and NA in PFS (p=0.0045; Figure 1). Discussion In non-transplant MM pts, we did not find a significant difference in the patterns of disease relapse between those treated with CA versus NA. Baseline characteristics such as renal failure or type of treatment do not seem to predict for the pattern of relapse; except the presence of 17p deletion trended toward more treatment failure. We note that the number of pts with aggressive relapses (plasmacytomas or plasma cell leukemia) was low and this limits our ability to detect differences in outcomes and baseline factors. Pts treated with NA continue to have better RR and PFS than those treated with CA. Future work with longer follow-up intervals is needed in order to capture late relapses, better describe relapse patterns with NA as well as understanding disease biology. Disclosures Chen: Celgene: Consultancy, Honoraria, Research Funding. Prica:Janssen: Honoraria; Celgene: Honoraria. Reece:Lundbeck: Honoraria; Janssen-Cilag: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Millennium Takeda: Research Funding; Bristol-Myers Squibb: Research Funding; Otsuka: Research Funding; Novartis: Honoraria, Research Funding; Onyx: Consultancy; Amgen: Honoraria; Celgene: Consultancy, Honoraria, Research Funding. Tiedemann:Janssen Ortho: Honoraria; Celgene: Honoraria; Amgen: Honoraria. Kukreti:Celgene: Honoraria; Amgen: Honoraria; Lundbeck: Honoraria; Roche: Honoraria; Janssen Ortho: Honoraria.
25
Locatelli, M. A., G. Curigliano, L. Fumagalli, R. Ghisini, P. Mancuso, F. Bertolini, G. Viale, L. Lunghi, and A. Goldhirsch. "Bevacizumab and oral chemotherapy for patients with lymphangitic breast cancer: A phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 1031. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1031.
Анотація:
1031 Background: Antiangiogenic agents are most likely to be effective in patients (pts) with an extensive cutaneous neo-angiogenic trait of disease. There is a compelling need to monitor the biological activity of such agents and identify markers of efficacy. Methods: We evaluated the activity and biological effects of bevacizumab (B) (15 mg/kg, iv q 3 weeks) in a phase II randomized trial in pts with locally advanced breast cancer (BC) with lymphangitic spread to the chest wall. Primary aim was to assess activity and toxicity of B administered alone followed by sequential oral vinorelbine (V) plus capecitabine (C) (arm A) or with concurrent V plus C (arm B). Secondary aim was to evaluate predictive role of circulating progenitor cells (CECs) and progenitor endothelial cells (CEPs) as surrogate markers of antiangiogenic activity. We collected blood samples of all pts at baseline, at day 12, 42, and at progression. Results: Planned accrual was of 43 pts of whom 23 were enrolled (9 pts in arm A; 14 pts in arm B). Median age was 51 years (range 35–68). Most of the pts had a “triple negative” phenotype [19/23 (82%)]. 10/23 pts (43%) received ≥ 2 previous lines of chemotherapy. 19 pts (82 %) are evaluable for response and all 23 pts are evaluable for toxicity. We observed 5 PR (45%) and 6 SD (55%) in arm B. In arm A, while on B alone, 6 (75%) of the pts had PD and 2 (25%) had a short term SD. Adding VC to B 2 PR (25%), 3 SD (37.5%), and 3 PD (37.5%) were observed. Toxicity profile was typical for use of B (hypertension). The absolute mean number of CECs was 158/ml (range 45–461) (n = 23) at baseline, 116/ml at +12 (range 47–275), and 194/ml at +42 (range 36–891). Mean absolute value of CEPs was 270 (range 28–1060) at baseline, 245/ml at D+12 (range 14–981), and 143/ml (range 5–610) at D+42. The fraction of apoptotic/necrotic CECs was 54±19% at baseline, 64±21 at+12, and 52±18 at+42. Conclusions: Preliminary data showed that B alone is not an effective treatment in pts with lymphangitic spread of BC to the chest wall. Additional data on CECs and CEPs are needed to clarify their potential usefulness as a surrogate markers of antiangiogenic activity of B-based regimen. No significant financial relationships to disclose.
26
Yock, Torunn I., Jackie Szymonifka, Alison M. Friedmann, Anita Mahajan, Beow Yong Yeap, Shannon M. MacDonald, Hallie Bieber Kasper, David Grosshans, Karen Chayt Marcus, and Nancy Tarbell. "Proton radiotherapy for rhabomyosarcoma: Preliminary results from a multicenter prospective study." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 9585. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.9585.
Анотація:
9585 Background: Pediatric rhabdomyosarcoma (RMS) is commonly cured with chemotherapy and radiation. However, late effects of radiotherapy (RT) can be disabling. Proton RT irradiates less normal tissue, which should result in fewer late side effects of treatment. The purpose of this study was to describe the disease control and side effect profile of proton RT in RMS patients (pts). Methods: Eligible pts included those with localized disease and metastatic embryonal RMS if age 2-10. All pts were treated with VAC (vincristine, actinomycin, cyclophosphamide) based chemotherapy and proton RT, median dose 50.4 Gy (36-50.4 GyRBE). Concurrent enrollment in COG protocols was allowed. All pathology/imaging was reviewed at the treating institution. Results: 47 pts with RMS were prospectively enrolled from January 2005 to June 2011 and evaluable for analysis. Median age was 3.1 yrs, (range 0.6-15.6 years; M/F ratio 23:24). There were 1, 7, 37, and 2 Group I, II, III and IV and 14, 12, 19 and 2, Stage I-IV pts respectively, and 33 with embryonal 14 with alveolar/other. Most common sites included PM (48.9%), orbital (23.4%) bladder/prostate (6.4%), H&N non-PM (6.4%), extremities (4.3%), trunk/abdomen 2.1%), perineal/anal region (2.1%) and other (6.4%). Median follow-up is 15.2 months. One/two-year overall survival (OS) and progression-free survival (PFS) for the entire group is 94/81% (OS) and 79/73% (PFS). 2-year OS for stage I,II/III,IV pts is 91/66% (OS, p=0.114) and two-year PFS for these pts is 86/57%, respectively, (p=0.083. 16 (34%) had grade 3/4 acute toxicities attributable to the radiation during treatment, the most common of which was mucositis/oral pain (12.8%), anorexia (4.3%), and erythema (4.3%). Among the 24 pts analyzable for late toxicities with at least 2 yrs of follow up, there were no grade 3 or 4 late toxicities attributable to radiation. Conclusions: Early results of this prospective trial demonstrate comparable disease outcomes and thus far limited late effects in a young pediatric RMS population. However, additional follow up is needed to determine if protons truly reduce rates and severity of late effects compared with photon cohorts published in the literature.
27
Bomben, Riccardo, Michele Dal-Bo, Dania Benedetti, Daniela Capello, Francesco Forconi, Daniela Marconi, Francesco Bertoni, et al. "Chronic Lymphocytic Leukemia Subset Expressing Mutated IGHV3-23 Has Peculiar Clinical and Biological Features." Blood 114, no. 22 (November 20, 2009): 1256. http://dx.doi.org/10.1182/blood.v114.22.1256.1256.
Анотація:
Abstract Abstract 1256 Poster Board I-278 Introduction In the last years, the B cell receptor (BCR) has become a key molecule in chronic lymphocytic leukemia (CLL), given the correlation between mutational status of immunoglobulin heavy chain variable (IGHV) genes and disease prognosis. Recently, a fraction of CLL has been shown to preferentially express specific IGHV genes, often in a non-random combination with homologous heavy chain complementarity-determining region-3 (HCDR3) and peculiar light chains. Some of these stereotyped BCR mark CLL subsets with peculiar clinical behavior regardless of IGHV mutations. These data suggest a role for BCR in defining the clinical and biological features of CLL, also beyond the mutational status of IGHV genes. Patients and Methods A HCDR3-driven clustering of 1,426 IG sequences (1,398 patients) was performed using ClustalX(1.83). Time to treatment (TTT) intervals, Rai staging, IGHV mutational status, CD38, ZAP-70, and karyotype abnormalities evaluated by FISH were available for 617 patients. Gene expression profiling (GEP) and quantitative real-time PCR experiments (QRT-PCR) were performed on purified CLL cells. Results IGHV3-23 was totally absent in 71 identified stereotyped clusters despite being the second most frequently used IGHV gene, such distribution was significantly skewed (p<0.0001), compared with the distribution of IGHV genes belonging to stereotyped BCR clusters observed in our series. Although 109/134 IGHV3-23 were mutated (M), alignment of IGHV sequences revealed a high degree of conservation in the context of the 13 AA positions involved in superantigen binding by IGHV3 subgroup genes, suggesting that the majority of M IGHV3-23 cases maintained the capacity to mediate superantigen recognition and binding. Median TTT (73 months) of 43 M IGHV3-23 CLL was significantly shorter than median TTT (253 months, p=0.0153) of 333 M CLL, as well as of 326 M CLL in which 7 cases belonging to the bad prognosis IGHV3-21/IGLV3-21 cluster were excluded (253 months, p=0.0082). Multivariate Cox proportional hazard analyses selected IGHV3-23 usage (p=0.029), Rai stage (p<0.0001) and FISH group (p<0.0001) as independent markers of disease progression for 376 M CLL, and for the cohort in which 7 M CLL from the IGHV3-21/IGLV3-21 cluster were excluded. Comparing 5 M IGHV3-23 and 22 M non-IGHV3-23 CLL for their differential GEP, 212 genes were selected, 108 up-regulated and 104 down-regulated in M IGHV3-23 CLL. Using the “Gene-Ontology Tree Machine” platform, a set of growth/tumor suppressor genes (PDCD4, TIA1, RASSF5), all down-regulated in M IGHV3-23 CLL, was constantly found in several gene-ontology categories related to apoptosis. QRT-PCR confirmed a significant down-regulation of these genes in 15 M IGHV3-23 compared to 35 M non-IGHV3-23 CLL. Given the notion that PDCD4 and TIA1 are among the genes under control of miR-15a and miR-16-1 a “Gene Set Enrichment Analysis” carried out on the 212 differentially expressed genes, confirmed that M IGHV3-23 samples were significantly deprived in genes whose expression is under control of miR-15a and miR-16-1. Accordingly, QRT-PCR experiments performed on 15 M IGHV3-23 and 35 M non-IGHV3-23 CLL revealed significant higher levels of both miR-15a (p=0.0007) and miR-16-1 (p=0.0031) in M IGHV3-23 cases. No difference was found in the distribution of patients with 13q14 deletion between M IGHV3-23 CLL and M non-IGHV3-23 CLL (p=0.19). Considering the cases used for microRNA expression experiments (data available in 47/50 cases), 8/15 M IGHV3-23 CLL bore the 13q14 deletion in more than 20% of nuclei, against 19/32 cases in the group of M non-IGHV3-23 CLL (p=0.94). Conclusion Expression of IGHV3-23 marks a subset of M CLL with a worse prognosis; such a peculiar clinical behavior may be related to superantigen stimulation combined with down-regulation of specific growth/tumor suppressor genes and up-regulation of miR-15a and miR-16-1. Disclosures No relevant conflicts of interest to declare.
28
Coutinho Filho, Bartolomeu Ribeiro, Thiago Miller Santana Silva, Carlos Eduardo Gonçales Barsotti, Francisco Prado Eugênio dos Santos, Jefferson Alves Galves, and Carlos Eduardo Algavez Soares de Oliveira. "Cifoplastia no tratamento da fratura vertebral por insuficiência: avaliação funcional prospectiva." Coluna/Columna 10, no. 3 (2011): 197–200. http://dx.doi.org/10.1590/s1808-18512011000300006.
Анотація:
OBJETIVO: Avaliar o resultado funcional e o grau de satisfação do tratamento cirúrgico utilizando cifoplastia em pacientes com fratura vertebral por insuficiência localizada na coluna tóraco-lombar. MÉTODOS: Foi realizado um estudo prospectivo em pacientes adultos, com diagnóstico de fratura vertebral por insuficiência com evolução superior a oito semanas, apresentando dor no local da fratura e edema ósseo evidente ao exame de RM. A avaliação funcional foi realizada através do Oswestry Disability Index 2.0 e da Escala Visual Analógica de Dor no pré- e pós-operatório. A satisfação pessoal com o tratamento foi quantificada pela escala de Johnson. RESULTADOS: Houve melhora significativa da dor com uma queda média de 6.4 pontos na Escala Visual Analógica de Dor ao final de doze meses de seguimento em comparação ao período pré-operatório (p < 00,5). A avaliação funcional mostrou 88% de resultados excelentes ou bons, sendo que sete pacientes (41%) apresentaram excelentes resultados e oito pacientes (47%) tiveram resultados bons. Dois pacientes (12%) mantiveram sua avaliação funcional inalterada. Quanto à graduação subjetiva de satisfação, 82% declararam-se satisfeitos sendo que 59% estavam completamente satisfeitos e 23% satisfeitos com mínimas restrições. Três pacientes (18%) declararam-se insatisfeitos com o resultado do procedimento. CONCLUSÃO: A cifoplastia mostrou-se efetiva em melhorar a função e liberar a dor em pacientes com fratura vertebral por insuficiência. A ocorrência de uma complicação grave (IAM) chama atenção para a necessidade de suporte hospitalar adequado durante a realização do procedimento.
29
Kellner, Christopher Paul, Alexander G. Chartrain, Dominic A. Nistal, Jacopo Scaggiante, Danny Hom, Saadi Ghatan, Joshua B. Bederson, and J. Mocco. "The Stereotactic Intracerebral Hemorrhage Underwater Blood Aspiration (SCUBA) technique for minimally invasive endoscopic intracerebral hemorrhage evacuation." Journal of NeuroInterventional Surgery 10, no. 8 (March 23, 2018): 771–76. http://dx.doi.org/10.1136/neurintsurg-2017-013719.
Анотація:
BackgroundEndoscopic intracerebral hemorrhage (ICH) evacuation techniques have gained interest as a potential therapeutic option. However, the instrumentation and techniques employed are still being refined to optimize hemostasis and evacuation efficiency.ObjectiveWe describe the application of a specific endoscopic technique in the treatment of ICH called the Stereotactic Intracerebral Hemorrhage Underwater Blood Aspiration (SCUBA) technique. It differs from previously described minimally invasive ICH interventions in that it combines two separate neuroendoscopic strategies in two phases, the first under dry-field conditions and the second using a wet-field strategy.MethodsAll patients who underwent endoscopic ICH evacuation with the SCUBA technique from December 2015 to September 2017 were included.ResultsThe SCUBA technique was performed in 47 patients. The average evacuation percentage was 88.2% (SD 20.8). Active bleeding identified to derive from a specific source was observed in 23 (48.9%) cases. Active bleeding was addressed with irrigation alone in five cases (10.6%) and required electrocautery in 18 cases (38.3%). Intraoperative bleeding occurred in 3 patients (6.4%) and postoperative bleeding occurred in a single case (2.1%).ConclusionsThe SCUBA technique provides surgeons with a defined strategy for true endoscopic hematoma evacuation. In particular, the fluid-filled cavity in SCUBA Phase 2 has the potential to provide several advantages over the traditional air-filled strategy, including clear identification and cauterization of bleeding vessels and visualization of residual clot burden. Further investigation is necessary to compare this technique to others that are currently used.
30
Racca, M. G., L. Ardouin, and M. García-Elías. "Correlación entre el ángulo de inclinación mediocarpiana y la morfología del semilunar." Revista Iberoamericana de Cirugía de la Mano 39, no. 01 (May 2011): 054–59. http://dx.doi.org/10.1055/s-0037-1606790.
Анотація:
Objetivo: Demostrar si existe correlación entre el ángulo denominado de Inclinación Mediocarpiana y el tipo de semilunar. Material y Método: Se estudiaron dos poblaciones: La primera fue de 100 pacientes con radiografías en posición póstero-anterior (PA) neutra. La segunda fue de 60 pacientes con radiografías PA en máxima desviación radial y cubital. Para cada una se determinó el tipo de semilunar por dos observadores independientes. Se propone un nuevo parámetro de análisis morfológico del carpo: el Ángulo de Inclinación Mediocarpiana. Resultados: En la primera población, 40 casos fueron clasificados como semilunar tipo I, 47 casos como tipo II. El promedio del ángulo de inclinación mediocarpiana fue de 56,3° (± 3,8) para el semilunar tipo I y de 67,5° (± 4,2) para el tipo II (p < 0.0001). En la segunda población, 23 casos fueron clasificados como semilunar tipo I, 19 casos como tipo II. El promedio de este ángulo, en las radiografías en máxima desviación radial fue de 59,5° (DS ± 6,4) para el semilunar de tipo I y de 69,4° (± 6) para el tipo II (p< 0,0001). En las radiografías en máxima desviación cubital el promedio fue de 51° (± 7,6) para en semilunar de tipo I y de 58,3° (± 7,4) para el tipo II (p= 0,003). Conclusiones: Este nuevo ángulo de inclinación mediocarpiana ofrece una herramienta más para determinar radiológicamente el tipo de semilunar, independientemente de la posición de la muñeca en el momento de obtener la radiografía.
31
Stengel, Anna, Wolfgang Kern, Melanie Zenger, Karolina Perglerová, Susanne Schnittger, Torsten Haferlach, and Claudia Haferlach. "A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker." Blood 124, no. 21 (December 6, 2014): 1639. http://dx.doi.org/10.1182/blood.v124.21.1639.1639.
Анотація:
Abstract Background: T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with poor prognosis. Only few T-PLL cases have been analyzed with regard to cytogenetic and molecular genetic aberrations so far. Therefore, we performed a comprehensive characterization of patients with T-PLL, including the identification of potential correlations between the respective markers and their impact on prognosis. Methods: The cohort comprised 47 T-PLL cases (32 male, 15 female). Median age was 69.8 years (range: 32.7-86.6 years). Diagnosis of T-PLL was assigned by immunophenotyping and cytomorphology. All 47 patients were further investigated using (i) chromosome banding analysis (CBA), (ii) interphase FISH to determine the copy number state for TP53 and ATM and chromosomal rearrangements of TCRA/D and TCL1 and (iii) array CGH. Next-generation amplicon deep-sequencing was performed to analyze mutations in ATM,BCOR, TP53 (n=47, respectively); JAK1 (n=44) and JAK3 (n=45) were analyzed by Sanger sequencing. Clinical follow-up data was available for 43 patients. Results: In all 47 cases, chromosomal abnormalities and/or molecular mutations were detected. Combining CBA and FISH data, an inv(14)(q11q32)/t(14;14)(q11;q32) was observed in 37/47 (78.7%) cases, a t(X;14)(q27;q11) in 3 cases (6.4%) and an i(8)(q10) in 17/47 (36.2%) cases. ATM deletions were detected in 27/47 (57.5%), TP53 deletions in 11/47 (23.4%) patients. Array CGH analyses revealed additional gains and losses of specific chromosomal regions, mainly affecting 7q (deletions in region 7q34-7q36; n=16), 12p (deletions in 12p12-12p13; n=11) and 22q (deletions in 22q11-q12 with a concomitant gain of 22q12-q13; n=8). Regarding molecular analyses, the most frequently mutated gene was ATM (34/47; 72.3%). Mutations in TP53 were found in 7/47 (14.9%) and in BCOR in 4/47 (8.5%) patients. Mutations of JAK1 were found in 3/44 (6.8%), and of JAK3 in 8/45 (17.8%) cases. ATM and TP53 frequently carried a mutation of one allele and a deletion of the other: 23/34 (67.6%) cases with ATM mutation also showed an ATM deletion and in 5/7 (71.4%) cases with TP53 mutation also a TP53 deletion was detected. Regarding chromosomal aberrations, all cases with i(8)(q10) harbored a TCRA/D rearrangement and an ATM mutation, whereas TP53 mutations were not present in any case with i(8)(q10). ATM mutations were found to be correlated to TCRA/D rearrangements (33/40 TCRA/D+ cases, 82.5%; 1/7 TCRA/D- cases, 14.3%; p<0.001). In contrast, TP53 mutations were predominantly observed in patients without TCRA/D rearrangement (4/7 TCRA/D- cases, 57.1%; 3/40 TCRA/D+ cases, 7.5%; p=0.008). Additionally, all three JAK1 mutations were detected in cases with a TCRA/D rearrangement. When splitting the cohort into patients ≤60 years (n=13) and >60 years (n=34), JAK1 mutations (0/12 vs. 3/32) and mutations/deletions in the TP53 gene were detected exclusively in patients >60 years (TP53mut: 0/13 vs. 7/34; TP53del: 0/13 vs. 11/34). JAK3 mutations were also found predominantly in older patients (1/12; 8.3% vs. 7/33; 21.2%). Median overall survival (OS) was 27.4 months. No influence on OS was found for mutations and/or deletions of ATM, TP53, BCOR orJAK1 or aberrations of chromosomes 8 or 14. The age of patients was found to impact OS (median OS, ≤60 years: 29.0 months vs. >60 years: 15.9 months), although this was not significant (p=0.077). However, OS was found to be significantly shorter in patients with JAK3 mutation compared to patients without JAK3 mutation (median OS, 5.1 months vs. 29.1 months; p=0.009). Conclusions: Genetic abnormalities were revealed in all 47 cases with T-PLL. Two distinct genetic subgroups of T-PLL were identified: A large subset, comprising 81% of patients, showed abnormalities involving the TCRA/D locus activating the proto-oncogenes TCL1 (14q32) or MTCP1 (Xq28). This subgroup had higher frequencies of i(8)(q10) and of ATM mutations, while the second group was characterized by a higher frequency of TP53 mutations (figure). Further, JAK3 mutations were identified as an important prognostic marker, showing a significant negative impact on OS. Figure 1: Genetic abnormalities in T-PLL Figure 1:. Genetic abnormalities in T-PLL mut=mutation, del=deletion, TCRA/D=rearrangements involving TCRA/D, TCL1=rearrangements involving TCL1, MTCP1= rearrangements involving MTCP1 Disclosures Stengel: MLL Munich Leukemia Laboratory: Employment. Kern:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Zenger:MLL Munich Leukemia Laboratory: Employment. Perglerová:MLL2 s.r.o.: Employment. Schnittger:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership.
32
Nagano, Osamu, Yoshinori Higuchi, Toru Serizawa, Junichi Ono, Shinji Matsuda, Iwao Yamakami, and Naokatsu Saeki. "Transient expansion of vestibular schwannoma following stereotactic radiosurgery." Journal of Neurosurgery 109, no. 5 (November 2008): 811–16. http://dx.doi.org/10.3171/jns/2008/109/11/0811.
Анотація:
Object The authors prospectively analyzed volume changes in vestibular schwannomas (VSs) after stereotactic radiosurgery. Methods One hundred consecutive patients with unilateral VS treated with Gamma Knife surgery (GKS) at Chiba Cardiovascular Center between 1998 and 2006 were analyzed in this study. For each lesion the Gd-enhanced volume was measured serially every 3 months in the 1st year, then every 6 months thereafter, using volumetric software. The frequency and degree of transient tumor expansion were documented and possible prognostic factors were analyzed. Concurrently, neurological deterioration involving trigeminal, facial, and cochlear nerve functions were also assessed. Results The mean observation period was 65 months (range 25–100 months). There were 32 men and 68 women, whose mean age was 59.1 years (range 29–80 years). Tumor volumes at GKS averaged 2.7 cm3 (range 0.1–13.2 cm3), and the lesions were irradiated at the mean 52.2% isodose line for the tumor margin (range 50–67%), with a mean dose of 12.2 Gy (range 10.5–13 Gy) at the periphery. The tumor volume was increased by 23% at 3 months and 27% at 6 months. Tumors shrank to their initial size over a mean period of 12 months. The maximum volume increase was < 10% (no significant increase) in 26 patients, 10–30% in 23, 30–50% in 22, 50–100% in 16, and > 100% in 13. The peak tumor expansion averaged 47% (range 0–613%). A high-dose (≥ 3.5 Gy/min) treatment appears to be the greatest risk factor for transient tumor expansion, although the difference did not reach statistical significance. Transient facial palsy and facial dysesthesia correlated strongly with tumor expansion, but only half of the hearing loss was coincident with this phenomenon. Conclusions Transient expansion of VSs after GKS was found to be much more frequent than previously reported, strongly suggesting a correlation with deterioration of facial and trigeminal nerve functions.
33
Yokom, Daniel, E. Celia Marginean, Derek J. Jonker, Allen M. Gown, Shelly Sud, Timothy R. Asmis, Manijeh Daneshmand, Horia Marginean, and Rachel Anne Goodwin. "Phosphorylated signal transducer and activator of transcription–3 (p-STAT3) expression concordance in paired primary and metastatic colorectal cancers (mCRC): Updated analysis." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e15137-e15137. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e15137.
Анотація:
e15137 Background: p-STAT3 is a transcription factor which is associated with poor prognosis in multiple cancers. Overexpression of p-STAT3 by immunohistochemistry (IHC) in tumors of patients with mCRC is associated with more aggressive disease and decreased survival. Concordance of p-STAT3 expression in primary and metastatic tumors was assessed to determine the temporal heterogeneity of expression and correlation with clinical outcomes. Methods: Patients with tissue available from both primary and liver metastases were identified retrospectively. Tissue microarrays (TMA) were constructed using 2 x 2mm cores. Nuclear p-STAT3 expression intensity by IHC was graded as absent, low, or high. Primary outcome was concordance of p-STAT3 expression between primary and metastatic sites. Secondary outcome was correlation of p-STAT3 expression with disease outcomes. Results: 91 patients were identified: 55% were male, median age at diagnosis was 63, 60% had left-sided disease and 81% of metastases were synchronous. Expression of p-STAT3 in primary tumors was 23% high, 47% low and absent in 30% compared to 29% high, 50% low, and 21% absent in metastases. Concordant expression was observed in 23% of patients whereas it increased in 46% and decreased in 31% from primary to metastasis. Pearson’s correlation was 0.119 indicating a weak concordance. After a median follow-up of 7 years, 50 of 91 patients died. One-year and 5-year survival rates were 92% and 44% respectively, while the median overall survival (mOS) was 4.7 years [95%CI 3.1-6.4]. No significant prognostic correlation between primary or metastatic p-STAT3 expression and mOS was found. Conclusions: There was low concordance of p-STAT3 expression in primary and metastatic tumors of patients with mCRC. Tumor staining heterogeneity due to sampling of small cores included in TMA and predominance of synchronous metastases may play a role. Further research in the use of p-STAT3 as a biomarker in patients with mCRC is needed.
34
Gartrell, Benjamin Adam, Giuseppe Del Priore, Avi S. Retter, Gerald H. Sokol, Alexander G. Vandell, and Mack Roach. "Typical hormone deprivation side effects compared to SM-88 therapy for rising PSA." Journal of Clinical Oncology 37, no. 7_suppl (March 1, 2019): 79. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.79.
Анотація:
79 Background: Treatment for rising PSA non-metastatic prostate cancer (nmPC) includes multifaceted hormone therapies (HT) associated with increasing related toxicity; in aggregate the risk benefit ratio is not ideal. We report on the use before HT, of SM-88, a novel combination therapy (amino acid analogue, CYP3A4 inducer, mTOR inhibitor and catalyst) based on the Warburg effect without known hormone related toxicity. Methods: Prospective ongoing Phase II of SM-88 (230 mg po bid) in recurrent nmPC with rising PSA (PCWG3 definition), no radiographically identified metastases at baseline and detectable CTCs. Results: From Sept 2016 to Dec 2017, there have been 31 consented (34 planned) with 23 evaluable (completed > 1 cycle). Mean age 68.9; BMI 28.7; 38% black and 62% post RT. Mean testosterone (T) rose from 319 to 382 ng/dl (p=.19). Typical HT related side-effects were not observed: 96% of subjects reported no hot flashes, 91% no gynecomastia, 83% interest and 61% activity in sex, 78% excellent or nearly so overall health and 74% excellent QOL on at least 50% of their EORTC questionnaires; weight (-0.2 kg), hct (0%), glu (+2 mg/dl), urinary N telopeptide (-4.2 nmol), MAP (normotensives -2 mmHg, hypertensives -3 mmHg), heart rate (-2.4 beats/min), QTc (-3 ms) with no newly emergent >480 ms, serum Ca++ (-0.006 mg/dL), LDH (+6.4 u/L), bsAlkPhos (+6.2 u/L), triglycerides (-5.2 mg/dL), total protein (0.05 g/dL) and albumin (0.02 g/dL). Neutrophil lymphocyte ratio decreased at the end of cycle 1 in 100% (n=5, median 2.4) of those who progressed to subsequent therapy vs 47% of those who did not (p=.05). AEs occurred in 16 subjects: 1 unrelated Grade (G) 3; 0 G 4; 14/26 G 1-2 possibly related to drug. No AEs were related to T levels. From initial diagnosis of PSA rise (median 9, 3-18 months), 96% (22/23) have remained metastases free and 78% (18/23) remained free of additional HT (p<.05). There were no skeletal or cardiovascular events. Conclusions: SM-88 may be useful in delaying the start of HT. While on SM88 subjects did not report any T or therapy related AEs >G2. SM88 may be useful in prostate cancer patients who are more sensitive or vulnerable to HT related toxicity while maintaining stable PSA values. Prospective trials are planned to confirm its utility. Clinical trial information: NCT02796898.
35
Bex, T., W. Chung, A. Baguet, S. Stegen, J. Stautemas, E. Achten, and W. Derave. "Muscle carnosine loading by beta-alanine supplementation is more pronounced in trained vs. untrained muscles." Journal of Applied Physiology 116, no. 2 (January 15, 2014): 204–9. http://dx.doi.org/10.1152/japplphysiol.01033.2013.
Анотація:
Carnosine occurs in high concentrations in human skeletal muscle and assists working capacity during high-intensity exercise. Chronic beta-alanine (BA) supplementation has consistently been shown to augment muscle carnosine concentration, but the effect of training on the carnosine loading efficiency is poorly understood. The aim of the present study was to compare muscle carnosine loading between trained and untrained arm and leg muscles. In a first study ( n = 17), reliability of carnosine quantification by proton magnetic resonance spectroscopy (1H-MRS) was evaluated in deltoid and triceps brachii muscles. In a second study, participants ( n = 35; 10 nonathletes, 10 cyclists, 10 swimmers, and 5 kayakers) were supplemented with 6.4 g/day of slow-release BA for 23 days. Carnosine content was evaluated in soleus, gastrocnemius medialis, and deltoid muscles by 1H-MRS. All the results are reported as arbitrary units. In the nonathletes, BA supplementation increased carnosine content by 47% in the arm and 33% in the leg muscles (not significant). In kayakers, the increase was more pronounced in arm (deltoid) vs. leg (soleus + gastrocnemius) muscles (0.089 vs. 0.049), whereas the reverse pattern was observed in cyclists (0.065 vs. 0.084). Swimmers had significantly higher increase in carnosine in both deltoid (0.107 vs. 0.065) and gastrocnemius muscle (0.082 vs. 0.051) compared with nonathletes. We showed that 1) carnosine content can be reliably measured by 1H-MRS in deltoid muscle, 2) carnosine loading is equally effective in arm vs. leg muscles of nonathletes, and 3) carnosine loading is more pronounced in trained vs. untrained muscles.
36
Alekhin, A. N., E. A. Trifonova, and A. V. Chernoray. "Attitude to disease in patients following cardiac emergencies." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 18, no. 4 (August 28, 2012): 317–24. http://dx.doi.org/10.18705/1607-419x-2012-18-4-317-324.
Анотація:
Objective. To assess attitudes toward disease in patients following cardiac emergencies at early stages of rehabilitation. Design and methods. The study sample consisted of 70 patients (23 females, 47 males) aged 35-67 years (54,5 ± 6,4 years old) hospitalized with myocardial infarction (MI; 55,7 %), unstable angina (18,6 %) or for planned cardiac surgery (25,7 %). The following methods were used: interview, medical records analysis, «Method for psychological diagnostics of attitude towards disease» (Wasserman L.I. et al., 2005). Results. Most patients (48,6 %) have «ergopathic» attitude toward disease characterized by aspiration to overcome disease in order to maintain the level of social activity they had had before the hospitalization. Denial of illness itself was found in 22,9 % cases, denial of possible illness consequences — in 51,4 %. Females, patients with recurrent cardiac attack and those, who had emergent (versus planned) hospitalization were more frustrated by the disease. Males and patients, who survived MI for the first time, were more prone to deny the fact of the disease as well as its possible consequences. Denial of the fact of illness was typical only of patients with the most life-threatening states — MI (compared to unstable angina). This may be regarded as an evidence of defensive/protective character of illness denial. Conclusion. Resistance, active overcoming and denial are predominant psychological tendencies in reaction to illness in patients following cardiac emergencies at early stages of rehabilitation. In case of ineffectiveness of these psychological strategies there is an increased risk of psychosocial disturbances. These characteristics of attitude toward illness in cardiac patients should be taken into account in the treatment and rehabilitation process.
37
Majoko, F., L. Nystrom, S. Munjanja, E. Mason, and G. Lindmark. "Does maternity care improve pregnancy outcomes in women with previous complications? A study from Zimbabwe." Tropical Doctor 35, no. 4 (October 1, 2005): 195–98. http://dx.doi.org/10.1258/004947505774938710.
Анотація:
To determine the utilization of maternal health care services and pregnancy outcomes for women with a history of complications in previous pregnancy, we analysed the pregnancy records of multiparous women (parity - 1) who booked and completed follow-up in Gutu district, Zimbabwe between January 1995 and June 1998. Women with previous uncomplicated pregnancies ( n = 6140) were classified as low risk, whereas those with complications of previous pregnancy ( n = 1077) were classified high risk. At enrolment, there was no difference in maternal age and parity between low- and high-risk women. A higher proportion of high-risk women had more than five antenatal visits (32% versus 21%; P<0.001) and gave birth in hospital (47% versus 18%; P<0.001). The risk of antenatal (relative risk [RR] 1.57; 95% confidence interval [CI] 1.32-1.88), labour/delivery (RR 1.98; 95% CI 1.75-2.25) and neonatal (RR 1.83; 95% CI 1.44-2.34) complications was elevated in high-risk women. There was increased risk for perinatal death in high-risk women, but this did not reach statistical significance (RR 1.56; 95% CI 0.98-2.49). The recurrence ratio for most complications was low and the sensitivity of historical risk markers in predicting women likely to develop further complicated pregnancies was only 23%. Most women with previous pregnancy complications can safely give birth in the rural health centre. We concluded that high-risk women had an elevated risk of complications in the index pregnancy and that better utilization of maternal health care, especially for delivery, reduced adverse perinatal outcomes.
38
Malpartida, Juan Carlos, Eric Vick, Noah Hunter Richardson, Kruti Patel, Matthew K. Stein, and Michael Gary Martin. "Distribution of ETV6-NTRK3 translocations across neoplasms identified from the Mitelman Database." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): e23141-e23141. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e23141.
Анотація:
e23141 Background: Discovered as a novel aberration in congenital fibrosarcoma (CF), the ETV6-NTRK3 translocation (EN) confers oncogenic potential and is inhibited by crizotinib. The present study aims to survey the scope of neoplasms that harbor EN across tumor types. Methods: Utilizing the National Cancer Institute’s Mitelman Database (MD) of Chromosome Aberrations and Gene Fusions patients (pts) were identified with EN and categorized based on tumor type, subtype and incidence. Cancer pts who received tumor profiling with Caris were also surveyed for EN. Results: 47 pts with EN across 12 cancer types were extracted from the MD and had median age of 0.17 years (7 unreported); 38% male; 51% acquired malignancies, 49% congenital; 62% cases were pediatric, 23% adult and 15% unknown. 0/204 pts with Caris tumor profiling were found to have an EN. Cancers with the highest number of EN were: 15 (31.9% EN data set) congenital mesoblastic nephromas (CMN), 10 (21.3%) CF, 7 (14.9%) breast carcinoma (BC; 6 secretory ductal carcinoma (SD) and 1 invasive adenocarcinoma (IA)) and 3 (6.4%) colorectal carcinoma (CRC). EN were found in 8 other malignancies (Table 1). Cancer types with the highest incidence of EN+ cases in the MD were gastrointestinal stromal tumor (GIST; 100%), CMN (75%) and CF (23.3%). Conclusions: These results further our understanding of the distribution of ETV6-NTRK3 translocations in multiple tumor types across the age spectrum and suggest that pts with CMN, CF, BC and CRC requiring high order therapy should be considered for NTRK3-based treatment. [Table: see text]
39
Ortigues, Isabelle, T. Smith, J. D. Oldham, A. B. McAllan, and J. W. Siviter. "Nutrient supply and growth of cattle offered straw-based diets." British Journal of Nutrition 62, no. 3 (November 1989): 601–19. http://dx.doi.org/10.1079/bjn19890061.
Анотація:
An experiment was conducted using steers cannulated at the rumen, duodenum and ileum to study the effects of increasing the levels of barley and fishmeal in straw-based diets. Diets A, B, C and D contained ammonia-treated straw, barley and fishmeal in the ratios, 67:33:0, 66:23:11, 53:47:0 and 52:36:12 (by weight) and were offered in daily amounts of 3·9, 3·9, 4·8 and 4·8 kg dry matter. The effects of barley were attributable to increased intakes of digestible organic matter and consequently to increased flows of microbial matter to the duodenum. There were no modifications in the balance of energy to nitrogen-yielding nutrients available for absorption. Introducing fishmeal into diets improved digestibility of cellulose and xylose by up to 6.7 and 4.7 % respectively, and shifted digestion towards the large intestine. Second, it increased amino acid N supply to the small intestine which averaged 52·2, 63·2, 68·8 and 84·0 g/d with diets A, B, C and D. Some changes were also noted in the balance of amino acids absorbed. Consequently, the contribution of amino acids to metabolizable energy intake increased with the proportion of fishmeal in diets (0·17, 0·20, 0·18 and 0·21 for diets A, B, C and D).Growth rates measured in heifers amounted to 259, 431, 522 and 615 g/d for diets A, B, C and D. They appeared to be related to intestinal amino acid supply.
40
Buesing, Jessica, Yingjie Weng, John Kugler, Libo Wang, Ondrej Blaha, Jason Hom, Neera Ahuja, and Andre Kumar. "Handheld Ultrasound Device Usage and Image Acquisition Ability Among Internal Medicine Trainees: A Randomized Trial." Journal of Graduate Medical Education 13, no. 1 (February 1, 2021): 76–82. http://dx.doi.org/10.4300/jgme-d-20-00355.1.
Анотація:
ABSTRACT Background There is insufficient knowledge about how personal access to handheld ultrasound devices (HUDs) improves trainee learning with point-of-care ultrasound (POCUS). Objective To assess whether HUDs, alongside a yearlong lecture series, improved trainee POCUS usage and ability to acquire images. Methods Internal medicine intern physicians (n = 47) at a single institution from 2017 to 2018 were randomized 1:1 to receive personal HUDs (n = 24) for patient care/self-directed learning vs no-HUDs (n = 23). All interns received a repeated lecture series on cardiac, thoracic, and abdominal POCUS. Main outcome measures included self-reported HUD usage rates and post-intervention assessment scores using the Rapid Assessment of Competency in Echocardiography (RACE) scale between HUD and no-HUD groups. Results HUD interns reported performing POCUS assessments on patients a mean 6.8 (SD 2.2) times per week vs 6.4 (SD 2.9) times per week in non-HUD arm (P = .66). There was no relationship between the number of self-reported examinations per week and a trainee's post-intervention RACE score (rho = 0.022, P = .95). HUD interns did not have significantly higher post-intervention RACE scores (median HUD score 17.0 vs no-HUD score 17.8; P = .72). Trainee confidence with cardiac POCUS did not correlate with RACE scores. Conclusions Personal HUDs without direct supervision did not increase the amount of POCUS usage or improve interns' acquisition abilities. Interns who reported performing more examinations per week did not have higher RACE scores. Improved HUD access and lectures without additional feedback may not improve POCUS mastery.
41
Virik, Kiran, and Robert Wilson. "Bone loss and vitamin D deficiency post gastrectomy for gastro-esophageal malignancy." Journal of Clinical Oncology 34, no. 4_suppl (February 1, 2016): 165. http://dx.doi.org/10.1200/jco.2016.34.4_suppl.165.
Анотація:
165 Background: Metabolic bone disease is a known but incompletely understood consequence of gastrectomy. Post gastrectomy osteoporosis (OP) is multifactorial. Evidence suggests that patients who undergo this surgery require long term bone health assessment and nutritional support. Methods: 30 post gastrectomy patients (2000-2008) from a single centre in Australia were evaluated re bone health post surgery and post nutritional supplementation. Exploratory analysis included: age, gender, pathology, type of surgery, 25 OH-vitamin D, calcium, parathyroid hormone (PTH), bone mineral density (BMD), vertebral XRs, urinary calcium and N telopeptides of type I collagen. Other risk factors evaluated were: smoking, corticosteroid use, alcohol intake, hyperthyroidism, menopausal status, hyperparathyroidism (hPTH), pre-existing bone disease. Results: The median age of the cohort was 67.5 (range 53-83) of whom 22 (73%) were male. Histology showed 16 (53%) gastric adenocarcinoma, 6 (20%) esophageal adenocarcinoma, 2 (7%) GISTs, 5 (17%) gastric/duodenal lymphoma and 1 other category. Similar numbers of patients underwent total (12) and partial/distal gastrectomy (12), with 6 having a subtotal gastrectomy. 22 (73%) had a Roux-en-Y or BR II reconstruction and 8 had a BRI/other. Median time from surgery to first BMD was 54.5 months (range 12-360) with median correlative calcium level 2.24 (range 1.97-2.49), median vitamin D level 43 (range 11-82) and median PTH 6.4 (range 1.8-13.8). Osteoporosis was diagnosed in 14 (47%) of patients, osteopenia in 14 and 2 (7%) patients had a normal BMD. Low vitamin D was seen in 23 (77%) patients, low calcium levels in 5 (17%) and secondary hPTH in 12 (41%). Post nutritional supplementation preliminary results showed 2/23 (9%) had a low vitamin D level, 3/11 (27%) had secondary hPTH, 5/19 (26%) had osteoporosis, 12/19 (63%) had osteopenia and 2/19 had a normal BMD. Analysis of other risk factors is to follow. Conclusions: Poor bone health and vitamin D deficiency is a clinically significant problem post gastrectomy. Patients should undergo long term nutritional and bone health surveillance in addition to their oncological follow up post resection.
42
Stelwagen, K., and D. G. Grieve. "Effect of plane of nutrition between 6 and 16 months of age on body composition, plasma hormone concentrations and first-lactation milk production in Holstein heifers." Canadian Journal of Animal Science 72, no. 2 (June 1, 1992): 337–46. http://dx.doi.org/10.4141/cjas92-041.
Анотація:
In a completely randomized design, 47 dairy heifers (6–8 mo of age) were assigned to a low (L), medium (M) or high (H) plane of nutrition to determine its effect on body composition (Slaughter Group, n = 23), subsequent first lactation (260 d) milk production (Production Group, n = 24) and blood somatotropin and insulin concentrations (n = 12 from each Slaughter and Production group). Actual daily gains between 6 and 16 mo of age were 611 g (L), 737 g (M) and 903 g (H). The proportion of carcass fat in heifers sacrificed at 16 mo increased while the proportion of lean and bone tissue decreased with increasing plane of nutrition. Concentrations of somatotropin measured at 9 and 14 mo of age decreased but insulin did not differ (9 mo) or tended (P < 0.10) to increase (14 mo) with increasing feeding level. Insulin concentrations at 9 and 14 mo of age were correlated positively with mammary crude protein and dry fat-free tissue at slaughter (9 mo, P < 0.05; 14 mo, P < 0.07), implying that insulin may play a role in mammogenesis in vivo. Plane of nutrition during the rearing period did not significantly affect production and composition of milk in the first lactation. It is speculated that this may be due to the fact that the heifers weighed approximately 200 kg at the start of the experiment, because recent research has demonstrated that the critical weight range during which mammary gland development is affected by plane of nutrition is between 90 and 200 kg. Key words: Heifer, somatotropin, insulin, lactation, plane of nutrition, body composition
43
Moffat, David A., Philip Grey, Robert H. Ballagh, and David G. Hardy. "Extended Temporal Bone Resection for Squamous Cell Carcinoma." Otolaryngology–Head and Neck Surgery 116, no. 6 (June 1997): 617–23. http://dx.doi.org/10.1016/s0194-5998(97)70237-7.
Анотація:
OBJECTIVE: The aim of this study was to assess the surgical results of a series of patients from this unit who underwent extended temporal bone resection for recurrent squamous cell carcinoma as a salvage procedure. DESIGN: The surgical records of 15 patients were analyzed in detail. Each patient had salvage surgery in the form of an extended temporal bone resection with supraomohyoid block dissection, dural grafting, and free microvascular forearm or scalp rotation flap repair for recurrent squamous cell carcinoma in a radical mastoid cavity. RESULTS: Radical surgery yielded a 47% 5-year survival. Twenty-nine percent of the survivors had temporal lobe involvement that necessitated a partial excision of the temporal lobe of the brain. Histologic evidence of local lymph node involvement in the supraomohyoid neck dissection was present in 13% of cases. Those who died did so in the first postoperative year. All those with poorly differentiated tumors died. The survivors had well or moderately differentiated tumors. CONCLUSIONS: Radiotherapy alone or partial temporal bone resection, most commonly a radical mastoidectomy with or without preoperative or postoperative radiotherapy is used by the majority of otolaryngologists in treating squamous cell carcinoma of the temporal bone. The 5-year survival rate after this treatment remains depressingly low and the prognosis gloomy, particularly for advanced tumors. The findings in this series of extended temporal bone resections as salvage surgery in recurrent disease is encouraging, and radical surgery combined with radiotherapy from the outset may give much better 5-year survival figures in the future than the conventional partial temporal bone resection and radiotherapy. (Otolaryngol Head Neck Surg 1997;116:617–23.)
44
Sugiura, Minoru, Mieko Nakamura, Kazunori Ogawa, Yoshinori Ikoma, and Masamichi Yano. "High serum carotenoids associated with lower risk for the metabolic syndrome and its components among Japanese subjects: Mikkabi cohort study." British Journal of Nutrition 114, no. 10 (September 14, 2015): 1674–82. http://dx.doi.org/10.1017/s0007114515003268.
Анотація:
AbstractRecent epidemiological studies show the association of carotenoids with the metabolic syndrome (MetS), but thorough longitudinal cohort studies regarding this association have not been well conducted. The objective of this study was to investigate longitudinally whether serum carotenoids are associated with the risk of developing the MetS and its components in Japanese subjects. We conducted a follow-up study on 1073 men and women aged 30–79 years at the baseline from the Mikkabi prospective cohort study. Those who participated in the baseline and completed follow-up surveys were examined longitudinally. Over the 10-year period, 910 subjects (295 men and 615 women) took part in the follow-up survey at least once. Over a mean follow-up period of 7·8 (sd 2·9) years, thirty-six men and thirty-one women developed new MetS. After adjustments for confounders, the hazard ratio (HR) for the MetS in the highest tertile of serum β-carotene against the lowest tertile was 0·47 (95 % CI 0·23, 0·95). On the other hand, significantly lower risks for dyslipidaemia were observed in the highest tertiles of serum α- and β-carotene and β-cryptoxanthin (HR 0·66; 95 % CI 0·46, 0·96; HR, 0·54; 95 % CI 0·37, 0·79; and HR 0·66; 95 % CI 0·44, 0·99, respectively). Other significant associations between the risks for obesity, high blood pressure and hyperglycaemia with serum carotenoids were not observed. Our results further support the hypothesis that eating a diet rich in carotenoids might help prevent the development of the MetS and its complications in Japanese subjects.
45
Nakagawa, Shigeto, Ryo Iuchi, Hiroto Hanai, Takehito Hirose, and Tatsuo Mae. "The Development Process of Bipolar Bone Defects From Primary to Recurrent Instability in Shoulders With Traumatic Anterior Instability." American Journal of Sports Medicine 47, no. 3 (January 23, 2019): 695–703. http://dx.doi.org/10.1177/0363546518819471.
Анотація:
Background: Recurrence of glenohumeral joint instability after primary traumatic anterior instability is not rare, and bipolar bone loss is one of the most critical factors for recurrent instability, but the development process of bipolar bone defects is still unclear. Purpose: To investigate the development process of bipolar bone defects from primary to recurrent instability among shoulders with traumatic anterior instability evaluated at least twice by computed tomography (CT). Study Design: Case series; Level of evidence, 4. Methods: There were 44 patients (47 shoulders) with recurrence after primary instability in which bone morphology was evaluated by 3-dimensional reconstructed CT at primary instability (initial CT) and after recurrence. As CT was performed 3 times for 3 shoulders including primary injury and the second episode of instability (first recurrence), there were 50 CT evaluations. Morphological changes between the initial CT evaluation at primary instability and the second CT evaluation at first recurrence were investigated for 25 shoulders, with the mean interval since initial CT being 9.8 months (range, 2-23 months). Changes between initial CT evaluation and final CT evaluation after ≥2 recurrences were also investigated for 25 shoulders, while the mean number of instability episodes including primary instability was 8.0 (range, 3-40) and the mean interval since initial CT was 18.5 months (range, 5-56 months). Results: At primary instability, the prevalence of Hill-Sachs lesions (66.0%) was almost double that of glenoid defects (34.0%), but their prevalence was different between shoulders with primary subluxation (42.3% and 23.8%, respectively) and those with primary dislocation (84.7% and 42.3%, respectively). After recurrence, glenoid defects became significantly more frequent (at first recurrence, 72%; after ≥2 recurrences, 76%), while Hill-Sachs lesions showed a smaller increase (88% and 80%, respectively), so there was no difference between the prevalence of the 2 lesions. The sizes of glenoid defects and Hill-Sachs lesions also enlarged after recurrence, and large bone defects were frequently recognized after recurrence. While bipolar bone loss was not so frequent at primary instability (29.8%), bipolar bone loss increased significantly after recurrence (at first recurrence, 72%; after ≥2 recurrences, 72%). All Hill-Sachs lesions were on track at primary instability, but off-track lesions were recognized in 3 of 47 shoulders (6.4%) after recurrence. Conclusion: In most shoulders with recurrent instability, a Hill-Sachs lesion developed first, followed by a glenoid defect, leading to bipolar bone loss. Off-track Hill-Sachs lesions were detected only after recurrence.
46
Tian, Ye, Zihong He, Jiexiu Zhao, Dalang Tao, Kuiyuan Xu, Adrian Midgley, and Lars McNaughton. "An 8-Year Longitudinal Study of Overreaching in 114 Elite Female Chinese Wrestlers." Journal of Athletic Training 50, no. 2 (February 1, 2015): 217–23. http://dx.doi.org/10.4085/1062-6050-49.3.57.
Анотація:
Context: Successful training involves structured overload but must avoid the combination of excessive overload and inadequate recovery. Objective: The aim of this study was to determine the incidence of functional overreaching (FOR), nonfunctional overreaching (NFOR), and overtraining syndrome in elite female wrestlers during their normal training and competition schedules and to explore the utility of blood markers for the early detection of overreaching. Classification of FOR, NFOR, and overtraining syndrome was based on the European Congress of Sports Medicine position statement. Design: Case series. Setting: China Institute of Sport Science. Patients or Other Participants: Over an 8-year period, 114 wrestlers from the women's Asian wrestling team were monitored to help identify if and when they experienced FOR, NFOR, or overtraining syndrome. Main Outcome Measure(s): Creatine kinase, hemoglobin, testosterone, and cortisol were measured throughout the period to identify whether wrestlers were outside the reference intervals (constructed from normal recovery data) during periods of overreaching and not overreaching. Results: Among the 114 athletes, there were 13 (3.6%) instances of FOR, 23 (6.4%) instances of NFOR, and 2 (0.6%) instances of overtraining syndrome. The diagnostic sensitivity for FOR was 38%, 15%, 45%, and 18% for creatine kinase, hemoglobin, testosterone, and cortisol, respectively. The diagnostic sensitivity for NFOR was 29%, 33%, 26%, and 35% for creatine kinase, hemoglobin, testosterone, and cortisol, respectively. Specificity was 79%, 88%, 90%, and 82% for creatine kinase, hemoglobin, testosterone, and cortisol, respectively. Post hoc analysis showed no mean differences in creatine kinase (F = 0.5, P = .47), hemoglobin (F = 3.8, P = .052), testosterone (F = 0.2, P = .62), or cortisol (F = 0.04, P = .85) between monitoring periods when wrestlers were and were not diagnosed with FOR and NFOR. Conclusions: Coaches and sports scientists should not use single blood variables as markers of overreaching in elite female wrestlers.
47
Hof, Jana, Stefanie Krentz, Claudia van Schewick, Gabriele Körner, Shabnam Shalapour, Peter Rhein, Leonid Karawajew, et al. "Mutations and Deletions of the TP53 Gene Predict Nonresponse to Treatment and Poor Outcome in First Relapse of Childhood Acute Lymphoblastic Leukemia." Journal of Clinical Oncology 29, no. 23 (August 10, 2011): 3185–93. http://dx.doi.org/10.1200/jco.2011.34.8144.
Анотація:
Purpose In the clinical management of children with relapsed acute lymphoblastic leukemia (ALL), treatment resistance remains a major challenge. Alterations of the TP53 gene are frequently associated with resistance to chemotherapy, but their significance in relapsed childhood ALL has remained controversial because of small studies. Patients and Methods Therefore, we systematically studied 265 first-relapse patients enrolled in the German Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Mü nster 2002 (ALL-REZ BFM 2002) trial for sequence and copy number alterations of the TP53 gene by using direct sequencing and multiplex ligation-dependent probe amplification. Results We observed copy number and sequence alterations of TP53 in 12.4% (27 of 218) of patients with B-cell precursor ALL and 6.4% (three of 47) of patients with T-cell ALL relapse. Backtracking to initial ALL in 23 matched samples revealed that 54% of all TP53 alterations were gained at relapse. Within B-cell precursor ALL, TP53 alterations were consistently associated with nonresponse to chemotherapy (P < .001) and poor event-free survival (P < .001) and overall survival rates (P = .002). TP53 alterations also had a significant impact on survival within intermediate-risk (S2) and high-risk (S3/S4) relapse patients (P = .007 and P = .019, respectively). This prognostic significance of TP53 alterations was confirmed in multivariate analysis. Besides their clinical impact, TP53 alterations were associated with a higher fraction of leukemic cells in S/G2-M phase of the cell cycle at relapse diagnosis. Conclusion Alterations of the TP53 gene are of particular importance in the relapse stage of childhood ALL, in which they independently predict high risk of treatment failure in a significant number of patients. Therefore, they will aid in future risk assessment of children with ALL relapse.
48
Rodriguez-Pascual, J., E. Garcia, F. Lopez-Rios, A. Cubillo, I. Diaz-Padilla, O. Hernando, L. Ugidos, I. Calvo, I. Duran, and M. Hidalgo. "Use of combined biomarkers analysis to predict response to chemotherapy in colorectal cancer: A single-institution feasibility study." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): 11074. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11074.
Анотація:
11074 Background: Treatment options for patients (pts) with colorectal cancer (CRC) have increased in the last years. However, there are no validated prospective molecular markers in CRC to select which agents are better to treat any individual case. The aim of this study was to determine the feasibility of developing an implementing a biomarker panel to guide treatment selection in this setting. Methods: Colorectal cancer tumors were prospectively analyzed with a predefined set of 11 molecular targets, including: KRas and PI3K mutations, EGFR amplification (FISH), and ERCC-1, TS, TP expression by IHC. Clinical characteristics and response to chemotherapy were registered. To establish the utility of this panel, we determine as congruent-treatment if the panel predict the best treatment in patients with more of 1 chemotherapy line and no-congruent-treatment if do not. Results: A total of 84 patients were studied. Only 6 % required a repeated biopsy to obtain sufficient tumor for marker analysis. In 81 % of patients was feasible to study almost 8/11 targets. There were 29 pts (39%) with KRas mutant CRC; 3 pts with PI3K mutations (4%, all of them with KRas mutation); and 2 patients with EGFR amplification. ERCC-1 was positive in 5/78 (6.4%) and TS was positive in 47%. None of 54 pts had TP positivity. Clinical floow up was available in 66 pts (44 males, median age 59, 93% ECOG 0–1). Nineteen patients had early CRC; 23 with metastatic CRC treated with a first line chemotherapy and 24 with advanced CRC treated with 2 or more prior regimens. In this last group for whom the response to multiple agents is known, the panel predictive the most effective treatment in 14 of 24 cases. Conclusions: This targeted-therapy-panel is feasible to implement and should be explore to predict treatment response to CRC . No significant financial relationships to disclose.
49
Hossain, AKM Farhad, Md Mahmudur Rahman Siddiqui, and Sayada Fatema Khatun. "Socio-demographic and Clinical Characteristics of Patient with Thyroid Cancer." Anwer Khan Modern Medical College Journal 11, no. 1 (February 27, 2020): 54–58. http://dx.doi.org/10.3329/akmmcj.v11i1.45668.
Анотація:
Background: Thyroid cancer is the most common malignant disease in endocrine system. It is an emerging public health issue associated with burden on the family, community and the nation. The aim of this study is to determine the socio-demographic and clinical characteristics of patient with thyroid cancer attending in tertiary hospital.
Methods: This cross sectional study was conducted among 246 thyroid cancer patients in two tertiary hospitals of Dhaka city from 01 July 2018 to 30 June 2019. The subjects were selected purposively following specific selection criteria and maintaining ethical issues. Data were collected by face to face interview using a semi-structured questionnaire and checklist. Data were analyzed by the statistical package for the social science (SPSS) version 23.
Results: This study revealed that majority (74.4%) of respondents was female, married (72%), housewife (61.4%), rural respondent (41.1%) and had primary education (69%). Mean (± SD) age of the respondent was 37.85(±12.20) years (Range 14-70 years) and mean (± SD) monthly family income was Tk. 17681(±10602). Out of 246 cases, 204 (82.9%) was papillary and 42 (17.1%) was follicular carcinoma. Various clinical presentations included visible neck swelling in 225 (91.5%), swollen lymph node in 103 (41.9%), pain 90 (36.6%), Difficulties in swallowing 87 (35.4%), Hoarseness of voice in 141 (57.3%), cough along with swelling 47(19.1%), Difficulties in breathing due to swelling in 13(5.3%) of the patients.
Conclusion: Incidence of thyroid cancer has increased worldwide specially in female patients in 3rd and 4th decades of life. As thyroid cancer is a growing public health problem in Bangladesh, proper screening and early diagnostic facilities at all level should be available to measure its actual burden in the country.
Anwer Khan Modern Medical College Journal Vol. 11, No. 1: Jan 2020, P 54-58
50
Syrogiannopoulos, George A., Ioanna N. Grivea, Maria Moriondo, Francesco Nieddu, Aspasia N. Michoula, and Chiara Azzari. "2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13." Open Forum Infectious Diseases 6, Supplement_2 (October 2019): S950—S951. http://dx.doi.org/10.1093/ofid/ofz360.2380.
Анотація:
Abstract Background We evaluated the long-term impact of full PCV13 vaccination in a 3 + 1 schedule on pneumococcal colonization patterns of children in order to clarify PCV13 serotype persistence/enhancement and re-colonization. Methods From January 18 to August 29, 2017, consecutive children who had received the 4-dose course of PCV13, as per the National Immunization Program recommendations, were prospectively enrolled through 45 general pediatric practice facilities in 30 municipalities in Greece. A single oropharyngeal sample was obtained from each subject in a standardized manner (questionnaire, procedure). Based on the time interval since the fourth dose of PCV13, the children sampled were grouped for analysis in 6 groups: 26 days to 11 months; 12–23 months; 24–35 months; 36–47 months; 48–59 months, and 60–71 months. Carriage and distribution of Streptococcus pneumoniae serotypes was detected by RT–PCR. Results A total of 1212 children aged 14–83 months were investigated. S. pneumoniae was identified in the pharyngeal swab of 617 children (50.9%); 172/617 (27.9%) children carried > 1 pneumococcal serotypes. As a consequence of co-colonization, a total number of 718 S. pneumoniae (belonging to 28 serotypes) was identified. The carriage rate of non-PCV13 serotypes escalated within 3 years after the fourth dose and plateaued during the fourth and fifth year. The carriage rate of PCV13 serotypes escalated during the 4 years after the fourth dose and declined thereafter. 22/305 children (7.2%) carried one or more PCV13 serotypes in the first year after the fourth vaccine dose, 27/201 (13.4%) in the second year, 34/207 (16.4%) in the third year, 48/224 (21.4%) in the fourth year, 40/191 (20.9%) in the fifth year and 13/84 (15.5%) in the sixth year (P < 0.0001) (Figure 1). The colonization frequency of serotypes 3 and 19A increased with the rise of the vaccination time interval (Figure 2). Changes in the frequency of other PCV13 serotypes were not significant. Serotypes 7F, 14 and 23F were not recovered. Conclusion Our study suggests that S. pneumoniae is present in the pharynx of children 26 days to 71 months after the completion of PCV13 vaccination, and that non-PCV13 serotypes predominate throughout this period. The carriage rate of PCV13 serotypes 3 and 19A increases significantly as the time interval from the fourth dose of PCV13 increases. Disclosures All authors: No reported disclosures.